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Abstract
Neurodegenerative diseases are a common affliction of the Central Nervous System. They
are caused by age, genetics, and environmental factors. Alzheimer's disease, Parkinson's disease,
Huntington's disease, and Amyotrophic Lateral Sclerosis are well-known among the host of
neurodegenerative disorders, with Alzheimer's disease and Parkinson's disease being the leading
pathologies across this canvas. It is known that the pathogenesis of neurodegenerative diseases is
multifactorial due to the involvement of genetic mutations, radical-induced protein damage,
abnormal aggregation of misfolded proteins, and the formation of amyloid deposits. The amyloid
proteins in neurodegenerative disease include Tau and Amyloid (Aβ) in Alzheimer's disease and
α-Synuclein in Parkinson's disease. The toxic form of these proteins is known to propagate across
the vertebrate brain.
Recent findings suggest that one pathological-associated protein can interact with another
sequentially unrelated amyloid protein. They tend to influence each other's aggregation and drive
neurodegenerative comorbidity. An example of this occurrence is the clinically overlapping
symptoms across several neurodegenerative disorders. For example, in Parkinson's disease, αSynuclein aggregates are copathological with Tau pathology in around 50% of cases. It is believed
that their seeding mechanism and cell-to-cell propagation leads to the activation of cellular
apoptosis, mitochondrial dysfunction, oxidative stress, accumulation of misfolded protein, and
ultimately, the loss of physiological functions. In this study, we evaluate the antioxidant capacity
of Brazilin in a cell line model, insulted by a truncated (Aβ 25-35) version of (Aβ 1-42). We tested
these phytochemical compounds' radical protect and anti-inhibitory capacity on the amyloidogenic
peptide. The result obtained suggest that Brazilin can scavenge free radicals, protect cells from Aβ
toxicity, inhibit protein aggregation and maintain cellular homeostasis. In addition, we designed a
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novel approach to understand the mechanism by which amyloid cross-toxicity propagates. Crosstoxicity is the phenomenon associated with the entry of an amyloid protein into a heterotypic brain
region, where the invading amyloid protein is not natively expressed. We probed the molecular
and organismal outcomes associated with foreign amyloid infiltration into neurons that do not
express it. Post stereotactic introduction of Aβ into the remote regions of the rodent brain
(Tegmentum) where Aβ is not constitutively expressed, we observed that Aβ colocalized with αSynuclein, nigral neuron amyloid that differs in sequence from Aβ. However, our model did not
elicit motor abnormalities in tested rats after 3,6,9,12-month post-infusion. Our results help us to
understand the role of a neuronal factor in cross-toxicity seen in many neurodegenerative diseases.
Environmental factors such as pesticides, herbicides, metals, among others, predispose the
organism to the onset of neurodegenerative diseases in later life, predominantly in urban areas.
These substances trigger neurotoxicity and overproduction of free radicals. Free radicals provoke
the aggregation of proteins, induce toxicity in dopaminergic neurons, and provoke mitochondrial
dysfunction. Next, we evaluated whether Citric Acid Carbon Quantum dots (Cit CQDs) protect
against Paraquat in Caenorhabditis elegans. Our result identifies that Cit CQDs possess a potent
antioxidant effect against Paraquat-induced neurodegeneration in dopaminergic neurons in C.
elegans and SH-SY5Y cell lines. Based on all findings presented in this study, Brazilin and Cit
CQDs have a potential therapeutic role in neurodegenerative diseases. Similarly, the novel animal
model designed in this study to evaluate cross-toxic outcomes helps us understand the mechanism
behind neurodegenerative disease at the molecular level.
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Chapter 1

Introduction
Xenobiotics are exogenous agents or foreign substances entering an organism that the body
does not express or recognize. Examples of xenobiotics are environmental agents, including
viruses, toxins, synthetics chemicals, and prions proteins. Some epidemiological studies have
linked xenobiotics to the onset of several neurodegenerative diseases (NDs).1,2
NDs are diseases united by the spread of amyloid and aggregation of misfolded proteins
leading to progressive loss of structure and function. Clinically, they are characterized by
irreversible degeneration, cellular dysfunction, and a steady decline in cognitive behavior.3
Diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral
sclerosis (ALS), and Huntington's disease (HD) are examples of NDs. AD and PD are the most
prevalent NDs, and advanced age is the significant risk factor. Both represent a significant public
health problem and substantial economic burden. It has been estimated that nearly 100 million
people worldwide are suffering from at least one of these neurological disorders, costing around
billions of dollars per year.4 This project is limited to studying the most predominant NDs today,
AD and PD. These two neuropathies have been thoroughly studied due to their increasing
prevalence worldwide. However, no cure has been found yet; their unclear etiology has stunted
the development of therapeutics.
Furthermore, current medical treatments only alleviate some of the patients' symptoms but
do not help prevent the progression of neurodegeneration and also, at times, possess highly harmful
side effects.5 Therefore, there is a considerable need for drugs with high tolerability, low toxicity,
and a broader array of targets that treat the symptoms and reverse the pathology. This project aims
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to design a new model that helps us better understand the co-pathology mechanism and create
novel therapeutic agents that help slow the disease's progression.
The amyloid proteins involved in these diseases include Tau and Aβ in AD and αSynuclein (α-Syn) in PD, which act as prion-like proteins. Despite their common characteristics,
they possess different mechanisms to make vulnerable subset cells selectively and brain
structures.6 This work examines the patho-biobehavioral deficits that may emerge upon
introducing an AD-associated amyloid protein proximity to a region affected in PD. Each disease
is associated with a harmful protein and distinct clinical syndromes. However, it has also been
shown that PD patients develop dementia and cognitive dysfunction, which are the principal
characteristics found in AD; since then, a relation in both neuropathies has been studied.7
Therefore, this work aims to help reconcile the high frequency of clinical comorbidity seen
in NDs and understand the mechanism of co-pathology. In particular, we focus on tackling some
challenges in the study of these diseases, such as the interactions of brain amyloid proteins in
diverse NDs, or why ∼30% to 40% of patients with PD present dementia during the disease course,
and ~30% of patients with AD develop locomotor deficits. Therefore, we design in vitro and in
vivo models to find similitudes between their behavioral and molecular mechanisms and target
them with plant-based compounds, and carbon nanomaterials.
1.1

MAIN CHALLENGES AND RESEARCH QUESTION
In the past, researchers have treated AD and PD as two different diseases, although at the

cellular level, it seems that the mechanisms of these two neuropathies may coincide.
Amyloidogenic proteins can spread and recruit other proteins generating new species responsible
for cellular toxicity, protein misfolding, and aggregation. It is important to understand how the
spread of an exogenous amyloidogenic protein may help with the progression of seemingly
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unrelated NDs. It seems that by recruiting other proteins involved in the heretofore unrelated
pathology. This cross-toxicity may explain why one pathological hallmark may act as a trigger
factor to provoke another. Would it be possible that a therapeutic agent that may inhibit the
formation of amyloid might be effective for several neurodegenerative disorders? What are the
molecular and organismal outcomes associated with infiltrating an amyloid seed into neurons
expressing different amyloid proteins? Can the infiltrating amyloid seed a nontoxic-to-toxic
conversion of the heterologous amyloid proteins?
1.2

DISSERTATION STRUCTURE
This dissertation is divided into three parts. The first focuses on recognizing challenges

and limitations in models to study and address the role of NDs that suffer from shortcomings.
Moreover, we focus on understanding the mechanism by which neurodegenerative disorders
present overlapping molecular and clinical symptoms. Introduction and general overview are
presented in chapters 1 and 2, respectively. Materials and methods used in this work are going to
be present in chapter 3.
In the second part of this dissertation, found in chapter 4, we focus on overcoming the
molecular mechanisms that lead to co-morbid in neurodegenerative disease. This chapter focuses
on evaluating the neurotherapeutic and neuroprotective effects of Brazilin, a plant-based
compound, that mitigates the cross-toxicity induced when a cell line model was truncated by Aβ
(25−35). Chapter 5 describes behavioral and molecular outcomes obtained after fragments of Aβs
were infused into the midbrain (Tegmentum) of wild type (WT) Lewis rat, an area where this
peptide is not constitutively expressed. Chapter 6 addresses the possible mechanism by which
Carbon Quantum dots (CQDs), a carbon-based nanomaterial of Citric Acid, protect dopaminergic
neurons of the nematodes. Caenorhabditis elegans (C. elegans) upon insult by the environmental
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toxicant Paraquat. Paraquat is an herbicide that has been used in many research studies due to the
high risk of developing neurological disorders such as PD from its commercial use. In the third
part, in chapter 7, we present the conclusion and future research directions.
1.3

DISSERTATION CONTRIBUTION
This dissertation includes in vitro and in vivo models' contributions to the field of NDs and

protein toxicity.
These contributions are:
1. We demonstrate the potent inhibitory and antioxidant capacity of Brazilin against Aβ
toxicity
2. We propose a vertebrate model design to explore the consequences of amyloidogenic
protein in a heterotypic environment
3. We present the protective role of Citric Acid CQDs on exposure of Paraquat in C. elegans
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Chapter 2
Mapping Neurodegenerative Diseases
2.1

DISEASES GENERAL OVERVIEW
This chapter provides a general overview of the background and previous related work

presented in the field. The soluble-to-toxic transformation of amyloid proteins is the hallmark of
many neurodegenerative diseases (NDs). Therefore, the neurological diagnosis of almost all of
them can be determined by aggregated proteins, each of which possesses different characteristics
and morphology. This is exemplified by Aβ oligomeric formation, hyperphosphorylated Tau
tangles in AD, and α-Syn aggregation in PD.
2.1.1

Alzheimer’s Disease and Structural Features
Alzheimer’s disease (AD) is the most significant cause of dementia, accounting for 50%-

75% of the cases. Its prevalence is expected to double from 6.2 million American patients to 12.9
million cases by 2050.5 AD is associated with two neuropathological features: the deposition of
insoluble extracellularly (Aβ) peptide (Aβ(1-42)) and the intracellular accumulation of
neurofibrillary tangles, the hyperphosphorylated Tau protein.8,9 Typically, AD appears to occur
sporadically and is classified as late-onset AD (LOAD) because it appears after 65 years. By
contrast, only a small fraction of patients suffers from familial AD (FAD). FAD is defined as earlyonset AD or (EOAD) and only represents less than 6% to 10% of all people with AD, with the rest
of the cases seemingly sporadic. 10 In EOAD, symptoms start showing in the 30s to mid’60s, and
they mainly result from a mutation on Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1),
and Presenilin-2 (PSEN2). 11,12 A modification in some genes causes increased production or
changes in the Aβs ratio. It has been demonstrated that a dysmetabolism of the APP is considered
triggering AD pathogenesis.11
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The most predominant forms of Aβ (1-40 and 1-42) are the principal peptide fragment
derived from the APP.12,13Our body in normal condition produces Aβ through the enzymes betasecretase and gamma-secretase (Amyloid-genetic pathway), and the cleavage by the toxic form,
alpha-secretase and gamma-secretase (non-amyloidogenic pathway).13The exact function of APP
is not well understood, and the same can be said for its cleavage product, Aβ (Figure 1).
Interestingly, the combination of these enzymes determines whether the product of this cleavage
is amyloidogenic or not.13–15
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Figure 1. Formation and Toxicity of Aβ Oligomers. Aβ is released
extracellularly as a proteolytically cleaved plasma membrane amyloid precursor protein (APP)
product. Figure reproduced from reference13
APP mutations near the cleavage sites provoke different products, and then, more of the
neurotoxic peptide will be generated. The toxic Aβ peptide fraction is the principal component of
amyloid plaques deposited extracellularly in the AD brain.16–18This peptide transforms into a small
soluble oligomeric that further forms chains of clusters called fibrils. When Aβ is soluble
oligomeric form, it starts to aggregate and spread (Figure 1).19,20 In the oligomeric form, Aβ can
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aggregate and disrupt cell communication, impact mitochondrial dysfunction, cause inflammation,
and induce inflammation endoplasmic reticulum (ER) stress, and also oxidative damage.13
Aβ peptide can undergo conformational changes into a misfolded and aggregated state,
provoking fibrillar cross-ß sheet amyloid aggregate (Figure 1). In the aggregation process, the
peptide initially in a soluble monomeric and native state undergoes an internal rearrangement to
misfold into a beta-sheet structure that eventually forms fibrils (Figure 1). It has been proposed
that the prefibrillar aggregates, as oligomers and protofibrils, could be the toxic components
instead of the fibrillar products. The formation of oligomeric structures, as shown in Figure 1, is
necessary to initiate the first protofibril structures, ultimately leading to the formation of the
amyloid fibrils.

13,21–23

Indeed, the non-native structure of misfolded oligomers could finally

interfere with several cellular components and processes that lead to a cascade of events in the
brain, such as mitochondrial dysfunction, calcium dysregulation, inflammatory reaction,
endoplasmic reticulum (ER) stress, oxidative stress which is elevated levels of reactive oxygen
species (ROS) and reactive nitrogen species (RNS).24–27
Oxidative stress induced by Aβ appears as a significant part of the pathophysiologic
process, occurring early in the AD brain. This oxidative activity occurs when ROS production
exceeds the natural antioxidant system. Moreover, it activates a cascade of events that may alter
APP’s or Tau’s normal processes. ROS are essential for maintaining oxygen homeostasis in
tissues. However, they can also cause oxidative changes, modify proteins, lipids, and nucleic acids,
and affect APP genes.28,29 Additionally, oxidative stress provokes damage to essential enzymes
involved in energy metabolism, neurotransmitter-related proteins, proteasomal components, and
damage to mitochondrial proteins. 30
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The proteolytic product of APP can be in the form of Aβ 1-40 and 1-42, but many studies
have been using a truncated fragment of this peptide, viz. Aβ 25-35. With only 11-amino acids out
of the full-length peptide (1-42), this small fragment can retain the toxicological features of the
native full-length peptide, as shown by apoptosis, decreased cell viability, ROS, and neuronal
DNA fragmentation.30–32 However, the mechanism is not well- understood. Still, it is believed that
the small peptide containing the following amino acids: GLY, SER, ASN, LYS, GLY, ALA, ILE,
ILE, GLY, LEU, MET, while the full peptide contains ASP-ALA-GLU-PHE-GLY-HIS-ASP-SERGLY-PHE-GLU-VAL-ARG-HIS-GLN-LYS-LEU-VAL-PHE-PHE-ALA-GLU-ASP-VAL-GLY-SERASN-LYS-GLY-ALA-ILE-ILE-GLY-LEU-MET-VAL-GLY-GLY-VAL-VAL-ILE-ALA can be more
toxic and cause oxidative stress similar to the full-length peptide. Finally, they have similarities in
terms of toxicity. The methionine residue in the 11-mer is in the C- terminal (end of an amino acid
chain), making it more toxic. When it becomes oxidized, it has been implicated in provoking more
damage than the full peptide.33 Met-35 of these peptides is critical for Aβ-induced toxicity and
oxidative stress.34 Finally, AD is characterized by many molecular changes (post-translational
modification) exerted by the Aβ peptide.12,31,34–36
2.1.2

Parkinson’s Disease and Structural Features
Parkinson's disease (PD) is the second most common neurodegenerative disorder. It

affects>1% of the population >65 years of age; with a prevalence set to double by 2040.37,38
Pathologically, it is characterized by the degeneration of dopaminergic (DA) neurons in the
Substantia Nigra (SN) projecting into the striatum (Figure 2).39,40 The loss of DA neurons in the
Substantia Nigra pars compacta (SNpc) leads to abnormal motor symptoms that affect the
execution of daily living activities of patients. SNpc contains the pigment neuromelanin, visibly
reduced in intensity in the post-mortem PD brain (Figure 2). Another critical pathological feature
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of PD is the accumulation of inclusion bodies, called Lewy bodies (LBS) and Lewy neurites
(LNS). Both consist of aggregated a-Synuclein (a-Syn) protein and post-translationally modified
protein products.41,42
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Figure 2. Substantia Nigra in PD. Representative image of the Substantia Nigra
in a healthy brain and the SN of a PD patients. Figure reproduced from reference.43

During Parkinson’s disease, patients present motor signs and a series of symptoms, such
as bradykinesia, resting tremor, muscular rigidity, and postural instability. Other non-motor
symptoms observed in PD patients are decreased gastrointestinal (GI) motility, difficulty
swallowing, breathing, speaking, loss of olfactory function, sleep disturbance, behavioral changes,
cognitive decline, and dementia.40 It is common in PD subjects that the non-motor symptoms
occur earlier than the motor symptoms.44However, the motor symptoms appear when there is
approximately 80-95% loss of DA neurons levels. This implies that significant cell death and
damage has occurred before any actual visible manifestation of the disease.45,46
As in AD, in PD, there are two subsets of this disease: sporadic and genetic. Most
Parkinson's disease patients (>95%) suffer from the sporadic variety of the disease. However,
mutations in 18 genes PAPK-1, PAPK-2, PAPK-3, PAPK-4, PAPK-5, among others, lead to
familial PD (<5%). 47a-Syn is a key protein in PD. a-Syn is found in the LB, consisting of a 140
9

amino acid polypeptide chain. It is expressed by the SNCA gene and can be found in multiple brain
regions such as the cerebellum, hippocampus, thalamus, and neocortex. 48The exact function of aSyn is still not well understood, but it is believed to be involved in synaptic vesicle trafficking and
recycling, which is thought to regulate the number of docked vesicles at the synapse site
neurotransmitter release by acting as a modulator in synaptic transmission. a-Syn can be found
near the presynaptic terminals but not in the synaptic vesicles. In healthy individuals, a-Syn was
found to help maintain proper functions of mitochondrial, ER, and autophagy clearance, among
other functions (Figure 3). However, in PD patients a-Syn tends to form aggregated and provokes
the dysfunction of the ER, mitochondrial, autophagic impairments, and LB and LN formation
(Figure 3). In its aggregated form, a-Syn follows nucleation-dependent aggregation kinetics,
which forms various transient species of amyloid aggregates, ultimately leading to amyloid fibrils
consisting of cross β-sheet rich structures. Several lines of evidence suggest that early forms of
oligomeric α-Syn are considered to cause protein inactivation, loss of function, mitochondrial
impairment, oligomerization of and a-Syn reduction of proteasome function (Figure 3).48,49
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Figure 3. Representative Image of a-Synuclein. a-Syn in a healthy and PD
patient. Figures reproduced from reference. 49
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Convincing evidence has shown that the common denominator between AD and PD is the
accumulation and aggregation of essential proteins for brain functioning.50 In NDs, one protein is
the causative agent capable of provoking the aggregation and misfolding of their proteins by acting
in a prion-like manner. As in AD with the toxicity of Tau and Aβ, a-Syn is commonly found in
PD. Consequently, a-Syn exhibits characteristics like those found in the infectious prion protein;
as an agent of self-replication, propagation, and transmissible neuropathy. 51 These effects are
characteristics of the prion phenomenon, as seen in AD with the seed of Aβ and Tau. a-Syn
toxicity can perturb the function of the nervous system and thus cause loss of function. Finally,
convincing evidence shows the molecular pathogenesis by which AD and PD biomarkers
contribute to the disease propagation, causing proteinopathy, heterotoxicity, mitochondrial
dysfunction, synucleinopathies, and oxidative stress. 26,52
2.2

OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES
Free radicals are molecules with one unpaired electron in the outermost shell. They are

highly reactive due to unpaired electrons. The free radicals involved in the production of oxygen
(O2) can be attributed to reactive oxygen species (ROS).53 ROS includes oxygen-related free
radicals and reactive species produced as a result of aerobic metabolism. The most common
cellular free radicals coming from O2 are hydroxyl (OH•), superoxide (O2•−), nitric oxide (NO•),
nitrogen dioxide (NO2•), peroxyl (ROO•) and lipid peroxyl (LOO•). In our daily life, some
molecules such as ozone (O3), peroxide (H2O2), nitrous acid (HNO2), peroxynitrite (ONOO-), lipid
peroxide (LOOH) are not considered free radicals but can easily lead to free radical reactions in
living organisms. 54 ROS has a usual metabolic role in cell signaling generated by the interaction
of (O2) and plays an essential double role in our living systems. A healthy level of ROS modulates
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several signaling pathways. However, at the same time, when they exceed normal physiological
levels, they do the opposite by playing pivotal functions in the pathophysiology of multiple
conditions (i.e., aging, cancer, diabetes, neurodegenerative diseases, and cardiovascular diseases)
(Figure 4).54 In conclusion, ROS at low or moderate levels is vital to human health. When
produced in excess, these highly reactive radicals can start a pathological chain reaction leading to
oxidative stress. Oxidative stress has been implicated in the progression of many diseases, as
mentioned above. Oxidative stress alters the cell membranes and other structures such as proteins,
lipids, lipoproteins, and DNA results from an imbalance between the production of reactive
oxygen and the biological system’s ability to detoxify the reactive intermediates leading to the
generation of toxic ROS (Figure 4).
In the CNS, the production of ROS has been linked to NDs due to the accumulation of
protein aggregates, increase in intracellular free Ca2+, autophagy and apoptosis. These mechanisms
play a critical role in the pathogenesis of many neurodegenerative disorders, such as AD and PD.
While brain neurons can cope with a rise in oxidative stress, select populations of neurons are more
vulnerable to it. They play a major role in AD, and it is believed that oxidative stress is stronger in
AD than in other NDs.53,55 Furthermore, the accumulation of misfolded protein in the aging brain
results in oxidative and inflammatory damage leading to energy failure and synaptic dysfunction.
As mentioned before, AD is characterized by Tau and Aβ accumulation in senile plaques. Aβ
deposition has also been shown to participate in a positive feedback loop, where the increase of
oxidative stress affects the APP and thus leads to increased Aβ generation. Conversely, the
mechanism of Aβ polymerization generates oxidative stress, which in turn enhances Aβ
production. As in AD, oxidative stress affects Aβ, in PD under conditions of oxidative stress aSyn would aggregate and form cytoplasmic inclusions bodies.53,55
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2.2.1

Antioxidants in Neurodegenerative Diseases
Antioxidants are both preventative and therapeutic options targeting oxidative stress. They

can be found exogenously and endogenously and act against any form of oxidative stress.53,54 The
mechanism by which antioxidants work to inhibit oxidative stress suggests that these compounds
can neutralize ROS and other free radicals by donating an electron or donating a hydrogen atom
via hemolysis which converts the radical species into a chemically more stable molecule.56
Exogenously, we can find these agents in many foods that contain antioxidants supplements. These
antioxidants include flavonoids, phenolic compounds, vitamin C, and β-carotene. Much evidence
has demonstrated that these antioxidants can prevent the oxidation of many proteins leading to
diseases. For example, Ginkgo Biloba, Epigallocatechin-3-gallate (EGCG), and Quercetin have
been found to possess excellent antioxidant properties that restrict Aβ toxicity after plaque
formation.53,56 On the other hand, endogenous enzymatic antioxidants act by neutralizing radicals
and transforming their precursors into less harmful molecules. In our body, we generate
antioxidant enzymes to fight against the overproduction of free radicals; these include catalase,
glutathione peroxidase (Gpx), peroxiredoxin (Prx), and superoxide dismutase (SOD).56,57
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Figure 4. Effect of Oxidative Stress in Humans. Exogenous and endogenous
sources of reactive oxygen species (ROS) and diseases.

2.3

PHYTOCHEMICALS AND CARBON QUANTUM DOTS APPLICATIONS
The NDs discussed earlier are part of the heterogeneous group of disorders with few

treatments available. Natural products have been obtained from plants for human benefit and tested
as therapeutics and prophylactics in NDs for many years. A significant portion of these compounds
are referred to as natural polyphenols (e.g., curcumin, rosmarinic acid, and ellagic acid), depending
on the structural moieties they present. They exhibit their activity by removing free radicals,
binding to metal ions, inhibiting enzymatic systems, and increasing the concentration of
biologically important endogenous antioxidants.53,54,58
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Neuroprotectants have gained more popularity after some in vitro, in vivo studies, and
clinical trials have shown promising effects on the disassembly and inhibition of misfolded
aggregates by acting as amyloid inhibitors.59 For example, in an in vitro study, using synthetic
Aβ, α-Syn, and EGCG, it was found that smaller amorphous protein aggregates were recorded
after 24−72 hours of incubation compared to controls in which mature fibrils had formed. Results
revealed that EGCG was able to remodel the structure of fibrillated amyloid proteins.60 In addition,
a study using 4.5 and 17-month-old mice EGCG was shown to reduce amyloid deposition in
animal models of protein misfolding disorders. Mice were treated for six weeks with EGCG 100
mg/kg/day via supplemented drinking water. Data demonstrated that a pre-treatment with EGCG
can reduce the level of several biomarkers. Amyloid deposition was decreased by about 50% in
the gastrointestinal tract and (PNS) compared with age-matched mice treated with water alone.60,61
Other natural compounds such as oleuropein aglycone and quercetin exhibit similar
features. They function by inhibiting fibrillization, inducing the disassembly of misfolded proteins,
and improving AD and PD phenotypes. Polyphenols are currently being used in clinical trials for
AD.5 These compounds could also protect cells and animals' models against the toxicity induced
by neurotoxicants such as neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine),
Rotenone, and Paraquat. Their antioxidant effects were due to generating neuro-protect through
its free-radical scavenging, iron-chelating, and anti-inflammatory properties. 62–66
Other types of compounds being introduced in the study of NDs are the use of Carbonbased nanomaterials (CNMs), such as carbon quantum dots (CQDs), carbon nanotubes (CNTs), or
graphene quantum dots (GQDs).66 They have shown the effect of mitigating NDs in vitro and
animal models' study. CQDs are synthesized using the green chemistry method to reduce aberrant
responses observed in environmental-toxicant-insulted models and inhibit the fibrillization of the
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Parkinson's Disease (PD)- associated amyloid α-Syn models. Some CQD, such as sodium citrate,
citric acid, and gelatin, have exerted antioxidant properties and important materials for several
biological applications. In an in vitro study using an amyloid-forming protein, Hen-egg white
lysozyme (HEWL), Sodium citrate CQD (Na-citrate CQDs) was able to interfere with the
formation of amyloid fibrils by preventing the formation of oligomeric lysozyme.66,67
2.4

MECHANISM OF PROTEIN TOXICITY

2.4.1

Protein Misfolding and Amyloid Formation
Proteins are one of the most important macromolecules for cell functioning. Therefore,

their correct folding process into a native functional state is essential for our body. A failure in
their folding process can trigger many pathological conditions that result in protein misfolding
diseases. 67 It is critical to describe the molecular mechanisms and implications of misfolded
proteins when discussing NDs.68 Specific proteins such as the Aβ and Tau in AD and a-Syn in
PD, among others, are implicated in the accumulation of misfolded aggregates commonly found
in neurodegenerative disorders (Figure 5). Peptides and proteins are converted into amyloid fibrils
from their soluble state into more highly organized fibrillar aggregates. 69,70 Amyloids are toxic to
the cells. The mechanism by which proteins misfolding aggregates are formed into amyloids is
through a seeding-nucleation model. Briefly, this process begins when peptides and proteins enter
in a slow and thermodynamically nucleation phase with their monomeric form and are rapidly
converted into oligomers following an elongation stage either by side by side or head to head to
later forms mature fibrils (Figure 6). 50,71
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Figure 5. Characteristic of Deposition of Abnormal Proteins in
Neurodegenerative Disease. (A) Represent the AD, neuritic plaque labeled for Aβ (cerebral
cortex). (B) AD, neuritic plaque, silver stained. (C) PD, Lewy bodies labeled for α-synuclein
(fine granular brown label in this and the next panel represent neuromelanin) (substantial nigra).
(D) PD, Lewy body, labeled for phosphorylated α-Synuclein (substantia nigra).Figure
reproduced from reference. 69
Typically, the first species formed during the aggregation step are found in clusters. At this
point, weak intermolecular interactions are implicated and may dissociate to become soluble
species. As the aggregation continues, these aggregates can internally reorganize to form
intermolecular β-sheet structures. This process ranges from small oligomers with self-association
or monomers to forming large fibrils aggregates.70 Such aggregates are ordered in 100-200 Å in
diameter with β-sheet intermolecular structures that can parallel the fibril's axis to form a structure
known as cross-β. These β-structure oligomers are highly dynamic and able to grow in equilibrium
with monomers and fibrils.50Misfolded oligomers are ill-defined and can be on-pathway for fibril
formation. Others can be the off-pathway byproduct of misfolded monomers, non-toxic oligomers,
and the culprit of neurodegeneration (Figure 7). The seeding features prevailing in each misfolded
protein can spread like infectious prion particles, a phenomenon known as a prion. The Nobel
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Prize, Stanley Prusiner, was the first in identified this infectious agent, the prion protein (PrP),
defined as proteinaceous contagious particles.72 This type of protein conformation becomes selfpropagating. The seeding feature of protein is a repeated characteristic of most misfolded proteins
found in many NDs that tend to behave like prions and drive specific patterns of pathology, such
as its capability to spread through the nervous system. 73–75

Figure 6. The Conformational States of Amyloid Proteins and the Inhibitory
Activity of Natural Phenolic Compounds. Figure reproduced from reference.76
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Figure 7. Spreading Pathway of Protein Misfolding and Aggregates at
Different Stages in NDs. Figure reproduced from reference 70
2.4.3

Pathogenic Protein Transmission and Propagation in NDs
One of the most significant advances in the study of protein misfolding and aggregation in

NDs has been the discovery of their ability to transfer pathological seeds between diseased and
healthy cells, referred to as "cell-to-cell or prion-like" transmission (Figure 7).77,78 The progressive
accumulation of specific pathological seeds, such as the Aβ, Tau, and a-Syn along with anatomical
connections, have provided the mechanism for understanding the genesis and progression of
multiple neurological disorders. It is interesting to know how brain regions are affected by
pathological seeds over time and how the patterns may vary from disease to disease. Experimental
evidence has demonstrated the molecular mechanisms that regulate the distribution process of
protein aggregates in disease brains (Figure 7-8). Recent studies in vitro and in vivo have found
that the mechanisms that modulate this transmission process follow a predictable spatiotemporal
pattern. 79
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In recent years, several preclinical studies using human brain tissues, animals and cells
models have been able to understand better and prove insight into the mechanisms of this disease
transmission model. Braak, H. has been one of the pioneers in studying this model; for example,
in post-mortem brain tissues of individuals with PD revealed that a-Syn pathologic protein has
been first found from the autonomic nervous system, dorsal motor, and olfactory bulb and then
spread to other areas such as the SN, forebrain, as wells as in the hippocampus and ultimately
extending to the cerebral cortex.80 Similar cases were found in AD patients when Tau first became
visible in the entorhinal cortex and locus coeruleus and later spread out to the hippocampal regions
and neocortex. On the other hand, the distribution of aggregated Aβ follows a distinct pattern from
Tau. The Aβ plaques were initially observed in the orbitofrontal neocortex and in the basal
temporal cortex, which later emerged right through the neocortex and then spread to the
hippocampus, brainstem midbrain, and cerebellum. 81
Data were collected from histopathological studies in which pathogenic aggregates isolated
from different brain regions of AD and PD patients were implanted in animals or cell lines. This
transmission hypothesis has been evidenced in patients who underwent cell transplantations using
brain-derived cells as therapy. In these cases, a-Syn aggregates were noticed in the grafted cells,
indicating that the transmission occurred from the host to the grafted cells.82,83 A similar trait
appeared with Tau and Aβ. Studies revealed that Tau was observed when brain extracts from
transgenic mice overexpressing Tau were injected into the brain of WT mice that do not naturally
express this protein. As a result, Tau aggregates were found in multiple brain regions, and a similar
result was obtained when human brain extracts were infused into mice brains.

84,85

Studies have

also demonstrated the cell-to-cell transmission of synthetic Aβ fibrils or extract from an AD patient
(Figure 8). Many reports have previously cited the idea that the aggregation of Aβ peptides with
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different sequences (1-42,1-40) was found in brain regions far from the original injection site,
albeit anatomically connected. This concludes that trans-synaptic transmission of Aβ pathogenic
seeds is occurring (Figure 8).86
Unlike Tau and a-Syn, the transmission model with Aβ aggregates has not been
successfully established in WT mice. This raises the idea that it could be due to a difference
between the Aβ found in mice and humans and the reason for the low transmission of Aβ plaques
in WT mice.75 In conclusion, when Tg and WT mice have been injected within the central nervous
system (CNS) or in the peripheral nervous system (PNS) with recombinant or isolated pathological
seed, propagation of the seed was found in distant brain regions. These examples support the
hypothesis that the stereotypical expansion of seed results from the "Prion-like" intercellular
transmission throughout anatomically related brain areas. Exist multiple mechanisms involved in
the secretion, uptake, and transportation of pathogenic aggregates between cells. The primary
secretion method to release the aggregates into the extracellular space is exocytosis, secretory
vesicles called exosomes, endocytosis, and tunneling nanotubes (Figure 8).87
In conclusion, pathogenic aggregates can be transferred through different secretory
methods to facilitate intercellular materials between connected brain networks. However, there is
still a need for more tools to address the behavior of pathogenic seeds in living human brains.72 It
is important to understand the molecular mechanism by which misfolding aggregates in NDs are
propagated in the brain to better design therapeutic interventions.

21

Copyright©

Figure 8. Potential mechanisms Mediating Cell-to-Cell Transmission of
Cytosolic Protein Aggregates. (a,b) Misfolded protein seeds (oligomers and protofibrils) first
form in the cytoplasm of the releasing neuron (left), where soluble native monomers are
recruited into large intracellular aggregates positive feedback loop can be initiated by the
generation of more seeds through fragmentation of secondary nucleation. A small amount of
protein aggregates can be released into the extracellular space in the 'naked' form (a) or via
membrane-bound vesicles such as exosomes (b). Free-floating seeds may directly penetrate the
plasma membrane of the recipient neuron (1) or enter by fluid-phase endocytosis (2) or receptormediated endocytosis (3), whereas exosomes containing seeds may fuse with the membrane of
the recipient neuron (4). Intercellular transfer of seeds may also occur by nanotubes that directly
connect the cytoplasm of two cells (5). Internalized seeds then nucleate the fibrillization of
native monomers in the cytoplasm of the recipient neuron. Figure reproduced from reference.87

2.4.3

Interaction of Pathological Proteins
The interactions between specific pathological proteins have been carefully studied since

patients suffering from one ND accumulate different pathological proteins.88,89 Recent findings
suggest a heterotoxic potential of these "seeds" whereby one neurodegeneration-associated protein
can interact with another sequentially unrelated prion-like protein, influence its aggregation, and
drive cross-toxic outcomes and neurodegenerative co-morbidity.88,89
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Since then, a relation of multi-brain amyloidosis in both neuropathies has been wellstudied. For example, it has been shown in post-mortem brains that ~50% of AD cases exhibit aSyn and LB and the primary components pertaining to the disease (i.e., the accumulation of Tau
and Aβ pathology in AD). Furthermore, ~50% of PD patients develop dementia and cognitive
dysfunction, principal characteristics found in AD and named as PD with dementia (PDD) or
(Lewy body variant of AD (DLB-AD). It has been demonstrated that patients with DLB-AD or
PDD commonly exhibit much more aggressive disease symptoms and more noticeable cognitive
dysfunctions than in patients suffering from the pure disease. The co-existence of these
pathological proteins has been hypothesized to promote the spreading of one another.81,90–92
A growing number of histopathological data support this hypothesis. For example, it has
been suggested that Aβ tends to spread Tau to other brain areas, primarily via the medial temporal
lobe. This was established when brain extracts of APP transgenic mice or exogenous synthetic Aβ
were found to promote Tau aggregation.93A similar results were obtained when a-Syn induced
Tau fibrillization in the cell and test tubes studies. In other studies, pathological a-Syn was also
able to promote Tau polymerization. 94 For example, a co-incubation of a-Syn and Tau were found
to promote pathological protein fibrillization of one another. Similarly, a study found an increase
in the phosphorylation of Tau in mice that overexpress a mutant form of human a-Syn.90,95
In a study using Tg mice model of Tau, Aβ, and a-Syn exhibited an increased level of all
three types of pathological proteins compared with mice models of each pathogenic
protein.90,96However, in other studies, when mice were injected with α-Syn fibrils or brain extracts
from other mice overexpressing mutant human α-Syn into APP Tg mice failed to promote Aβ
aggregation. 92,97,98The interaction between these two is more complicated to determine. Therefore,
more research is needed to understand the interaction between Aβ and α-Syn pathology. There is
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a need to study the molecular origins of neurodegeneration and their convergence. However,
developing experimental protocols to address the root cause of cross-pathology is even more
critical.
2.5

ANIMALS MODELS IN NEURODEGENERATIVE DISEASES
To understand the complexity of the mechanisms of diseases, model organisms are used as

surrogates for humans. Many Tg animal models have improved the diagnosis, prevention, and
treatments of many diseases. Modeling of NDs has been conducted in inbred rodents, such as rats
and mice. These two possess much of the same neurocircuitry that reproduces cellular and behavior
that only higher mammalian animals have, including humans. However, they can be expensive
and laborious to maintain and required ethical concern regarding testing potential drugs.99
Strategies such as using bacteria, immortalized, or primary cell culture have been used to
supplement in vivo studies. However, in vitro models lack the complexity that higher organisms
possess. In recognition of a need to combine a simple and a potent model organism with a shorter
generation time, organismal models such as S. Cerevisiae, C. elegans, zebrafish, and D.
melanogaster have been availed of. This work focuses on two established organismal models, viz.,
Lewis WT rats and transgenic C. elegans. Rat models are extensively used to study PD because
they can mimic significant dopaminergic lesions, as shown in motor deficit diseases similar to
those observed in humans. Rats also present with other visible deficits identical to those seen in
humans PD, such as hunched postures, rigidity, slowness of movements, depression, and the loss
of limb use. 99,100
The use of the roundworm microscopic nematodes C. elegans to define NDs' disease
mechanism, identify a novel gene, and drugs discovery has grown. Due to their small size (1mm),
rapid reproduction cycle (3 days), short lifespan (2-3 weeks), their transparent body, their ability
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to feed on bacteria Escherichia Coli (E. coli), are some of the advantages offered by this model.
Their complete sequenced genome is already identified, and it is also established that they have a
similar number of genes as humans (20,000), with >60 of the genes homologous to humans.
Additionally, it has been demonstrated that the C. elegans nervous system functionally
recapitulates some of the characteristics of the vertebrate brain. Human brains possess nearly 100
billion nerve cells, whereas these nematodes contain 302 neurons, making it possible to determine
their neuronal connectivity. Their simplicity allows scientists to make numerous transgenic
constructs (mutants). Some of these mutations endow the worm with a green fluorescent protein
(GFP) or other colors incorporated into their genome and enable researchers to visualize any
protein or gene of interest. 101–104
C. elegans have been used to study the accumulation of harmful diseases proteins and
neurotoxins-induced neuronal loss, such as the 1-methyl 4-phenyl 1,2,3,6-tetrahy- dropyridine
(MPTP), 6-hydroxydopamine (6-OHDA), and other pesticides like Rotenone and Paraquat.
Finally, this model has also been used for chemical screening that explores effective
pharmacological compounds and natural antioxidants that prevent loss of neuronal function in
NDs. It is recommended to use this model for this purpose before testing compounds in a higher
organism.101,102
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Chapter 3
Materials and Methods
3.1

CELLULAR BIOLOGY-BASED METHODS
The objective of this section was to determine the ability of phenolic compounds to prevent

Aβ (25-35)and Paraquat-induced pathogenesis. Here we discuss the methods used to develop and
test plant-derived compounds and carbon nanomaterial intervention in neuroproteopathies such as
AD and PD. Briefly, these include evaluation of Reactive Oxygen Species (ROS), mechanism of
cell death, aggregation of PD-associated biomarkers (α-Syn aggregations), Protein Disulfide
Isomerase (PDI), and the colocalization between proteins expression level in SH-SY5Y.
3.1.1

Chemicals, Cell Line and Materials
The following reagents were sourced commercially. The water used in all experiments

listed here was purified using a Milli Q water purification system. Cells SH-SY5Y were obtained
from (ATCC, Manassas, VA), cells medium (DMEM 398225) purchased from Sigma-Aldrich.
Fetal Bovine Serum (FBS) (R&D system), Brazilin (SML2132; Millipore-Sigma USA),
Propidium Iodide (PI -P1304MP; T. Fisher), and Hexafluoroisopropanol (HFIP) (105228;
Millipore-Sigma USA), respectively; human Aβ 25−35 (Ana Spec AS-24448); Annexin V kit
containing Annexin V-FITC (Beckman Coulter); 1,1- diphenyl-2-picryl-hydroxyl (DPPH;
Millipore-Sigma USA); Hoechst 33342 (Life Technology H1399); trypsin-EDTA 0.25% (Life
Technologies, 25200-056); protein disulfide isomerase (PDI) antibody, and α-synuclein (Cell
Signaling Technology; C81H6, 2647). Most of the secondary antibodies were obtained from
Abcam (Alexa Fluor 488 -ab150077, Texas red; ab6787), and Fluoro-Gel II Mounting Medium
was obtained from Fisher Scientific 17985-50. Egg white Lysozyme (CAS:12650-88-3),
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Thioflavin T(ThT) (CAS 2390-54-7), Methyl viologen dichloride hydrate (Paraquat (856177-1G))
were purchased from Sigma-Aldrich. The Penicillin/Streptomycin used in this study (15-140-122
Gibco). Citric acid anhydrous (A940-500; T Fisher, USA), Ammonium Bicarbonate (1066-33-7),
Guanidine Hydrochloride (50-01-1), Potassium Phosphate Dibasic and Monobasic (7758-11-4,
7778-77-0) were purchased from Fisher Scientific.
3.1.2

Amyloid-β Preparation
In collaboration with Erick Guerrero, various forms of Aβ (Ana Spec AS-24224, AS-

24448) were prepared and purified before being used in the cells and into the midbrain
(tegmentum). The size of Aβ oligomers is distributed over a broad molecular weight range (<10
kDa to >100 kDa). The oligomeric form of Aβ was prepared and separated from its monomeric
form by gel filtration chromatography, as described in "Preparation of amyloid β-protein for
functional studies.105 Briefly, a solution of 2 mg/ml Aβ in DMSO was freshly prepared. The
solution was sonicated for 1 min before being centrifuged for 10 min at 16,000 × g. The supernatant
was aspirated and fractionated using a Superdex 75 HR column (10 mM phosphate buffer, pH 7.4).
This procedure was adopted prior to using it in the cells and on the day of the stereotaxic infusion
to ensure that the solutions were fresh. The retention times of the monomer vs. oligomeric Aβ are
reproducibly different and were collected without cross-contamination. The separated fractions
upon collection were used immediately. Per literature reports, the solutions of Aβ (1-42) and Aβ
(25-35) were also freshly prepared before immediate use.
3.1.3

Dynamic Light Scattering (DLS)
Aβ (25−35) was dissolved in HFIP, aliquoted, and incubated at room temperature for at

least 30 minutes. The HFIP was allowed to evaporate, and the aliquots were stored at −20 °C.
Immediately before use, Aβ (25−35) was dissolved in DMSO. The size (monomer, oligomer,
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fibril) of Aβ (25−35) in solution was periodically measured using dynamic light scattering (DLS).
DLS was performed using a Malvern Zetasizer Nano ZS90, and a refractive index of 2.42 and
1.450 was used. The DLS was based on joining collaboration with Erick Guerrero.
3.1.4

Citric Acid Carbon Quantum Dots Synthesis
Carbon quantum dots (CQDs) were synthesized through a standard hydrothermal method.

Citric Acid (Cit) (2g,10.4 mM), and Ammonium Bicarbonate(0.13 M), the solution was dissolved
in 10 mL of water in an Erlenmeyer and held on the stove at 200°C for 30 minutes. After the
heating process, CQDs were cooled to room temperature, and pH was neutralized to biological
pH. Finally, the preparation was sonicated to separate them from agglomerated larger particles.
CQDs were purification by dialysis (24 hours). Dialysis was carried by using a one kDa molecular
weight cutoff dialysis tube protected from light. The purified CQDs solution was frozen at -80 °C
and lyophilized for long-term storage. Citric Acid CQDs were based on joining collaboration with
Erick Guerrero.
3.1.5

Citric Acid Carbon Quantum Dots Characterization
The UV/VIS spectra of N-doped Citric Acid (Cit CQDs) were observed using the

Chemglass Life Sciences SpecMate UV/Vis spectrophotometer. The morphology and size analysis
of the as-synthesized CQD was obtained using the Transmission Electron Microscopy (TEM)
(Hitachi High Technologies America). The IR spectra to determine surface chemistry of the assynthesized CQD were obtained using the Thermo Scientific Nicolet iS5 in the range 500-4000
cm-1. The excitation-dependent emission spectra of the Cit CQDs were obtained using the DM45
Olis spectrofluorimeter. Citric Acid CQDs characterization was based on joining collaboration
with Jyoti Ahlawat.
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3.1.6

Radical Scavenging Activity by DPPH Method.
The 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay was performed to measure the

antioxidant activity of our natural-based compounds and the as. DPPH is a violet-free radical
solution that fades to yellow in the presence of an antioxidant. Briefly, 2 mM of DPPH was freshly
prepared in methanol before use; Brazilin stock was prepared in DMSO and diluted. Solutions
were incubated for 5 minutes, and then spectrophotometric measurements were obtained at 517
nm. The percentage of free radical inhibition was calculated by using the following formula:
% 𝑜𝑓 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =

3.1.7
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Fluorescence Inhibition of Lysozyme Fibrillation
Lysozyme aggregates were prepared by dissolving 139 μM (2 mg/mL) of lysozyme in 20

mM KH2PO4 with 3 M guanidine hydrochloride at a pH of 6.3, for a total volume of 1.8 mL.
Brazilin was prepared as previously mentioned, dissolved in DMSO at a concentration of 5 μM,
and added to its vials. Vials were incubated for 5 hours at 60 °C at a constant agitation of 500 rpm.
After 5 hours, the formation of fibrils was observed. Samples were added to a Quartz cuvette,
followed by the addition of 20 μM ThT and measured using a DM45 Spectrofluorometer (On-Line
Instrument System, Inc.). A 2 min scan was performed at a constant integration time (0.1 s) using
an excitation and emission monochromator at 450 and 482 nm, respectively. All measurements
were performed in triplicate. The fluorescence study was based on join collaboration with Erick
Guerrero.
3.1.8

Cell culture
Human neuroblastoma cells (SH-SY5Y), a dopaminergic neuroblastomas cell line, is a

model that has been used to recapitulate the PD phenotype. Cells were grown in a culture medium
(DMEM/F12) supplemented with 10% fetal bovine serum (FBS). Antibiotic was added to the
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medium in 1 %v/v of penicillin/ streptomycin. Cells were maintained by incubation at 37°C with
5% carbon dioxide. All experiments were performed by seeding the cells into 96-, 24-, 12-, and 6well plates. Once confluent reached 80 to 90 %, the cells were then pretreated with Brazilin, diluted
in DMSO for 1 hour, Cit CQDs in DIH2O for 12 hours, followed by oligomeric Aβ (25−35)
dissolved in HFIP or Paraquat in DIH2O and incubated for 24 hours. All cell work was performed
at the Border Biomedical Research Center (BBRC)-The University of Texas at El Paso.
3.1.9

Measuring Cytotoxicity
Cytotoxicity of Brazilin, Aβ, Paraquat, and CQDs was measured to determine the CC50.

The cytotoxic potential was assayed by seeding ≥10,000 cells/well into a 96-well plate format with
a density of 100,000 cells per wells in 200µL of culture media. After cells reached 80 to 90 %
confluency, each well was treated with the prophylactic's compounds. Then, after 1 hour of
incubation at 37°C, cells were insulted with Aβ (25−35) (20µM) and Paraquat after 12 hours and
incubated for an additional 24. The plates were incubated at 37 °C in the presence of 5% carbon
dioxide with Brazilin (0.1 to 100 μM), Cit CQDs (10µg/mL to 1 mg/mL), Aβ25−35 (1µM to 50
µM) Paraquat (5µM to 2mM), and H2O2 as a positive control. Dual staining of Propidium iodide
(PI), a membrane-permeant used to detect dead cells, and Hoechst 33342 is used for staining live
cells (final concentration of 1 μg/mL each), were added to each well 1 hour before obtaining
readings. Images were acquired in a live-cell mode using a multiwell plate reader (IN-Cell 2000
automated microscopy system; GE Healthcare) equipped with a 10× objective and an IN-cell
analyzer 2000 acquisition v4.0 software (GE Healthcare). Four contiguous fields with a montage
of 2 × 2 were acquired per well and per fluorescence channel. Image capture and data analysis
were translated to an IN-Cell analyzer workstation v3.7.2 software (GE Healthcare), which was
used to achieve data segmentation of the images (thus providing the region of interest and the
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cytotoxicity percentages of cell death per each well). Each of the experiments was repeated eight
times.106
3.1.10 Detection of Apoptosis /Necrosis by Annexin V-FITC/PI Assay
We measured the mechanism of cell death induction upon Aβ (25−35). To gain insight into
the Aβ (25−35) mechanisms of action on SH-SY5Y neuroblastoma cells, we used the annexin VFITC (Beckman Coulter, Miami, FL, USA) and propidium iodide (PI) assay to investigate the
apoptosis or necrosis pathway. Cells were seeded in a 24-well plate with a density of 100,000 cells
per wells in 250µL of culture media. After cells reached 80 to 90 % confluency, each well was
treated with the prophylactic's compounds Braz (0.1 to 100 μM), and Cit CQDs (10µg/mL to 1
mg/mL), after 1 or 12 hours of incubation at 37°C,5% CO2, cells were insulted with Aβ
25−35(1µM to 50 µM). Cells were incubated for an additional 24 hours. Solvent (1%DMSO),
(1µM) H2O2, and untreated positive and negative control were included. The cells from each well
were harvested in flow cytometry tubes, washed with cold PBS, centrifuged for 5 minutes at 1,200
rpm, and resuspended with 100 µl of 1X binding buffer containing 1µL Annexin V-FITC and 5µL
PI per test, following manufacturer's instructions (Beckman Coulter). The cells were gently
resuspended with the mixture to facilitate the incubation of the fluorophores and placed for 15
minutes on ice protected from the light. Subsequently, an additional 400 μl of cold binding buffer
was added to the cell suspension. The mixture was gently homogenized and immediately analyzed
via flow cytometry (Gallios, Beckman Coulter) and the FL1 and FL2 detectors. The percentage of
apoptotic cells was defined as the sum of both early and late stages of apoptosis; annexin V-FITC
positive. Approximately 10,000 events (cells) were acquired and analyzed by using Kaluza
software (Beckman Coulter).
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3.1.11 Measuring the Level of Reactive Oxygen Species
The production of intracellular oxygen species (ROS) was measured via carboxy-H2
DCFDA(6-carboxy-2’,7’-dichlorodihydrofluorescein diacetate) fluorescein reagent (Invitrogen,
C400). Cells were seeding ≥10,000 cells/well into a 96-well plate. After cells reached 80 to 90%
confluency, wells were treated with the prophylactic's compounds. After 1 hour of incubation at
37°C, cells were insulted Paraquat (5µM to 2mM), and positive and negative controls (1%DMSO),
(1mM) H2O2, untreated) after 12 hours and incubated for an additional 24 hours. We used a
carboxy-H2 DCFH-DA probe at a final concentration of 10µM. This probe is a non-fluorescent
reagent

and

cell-permeable,

which

transformed

intracellularly

to

a

green

form

(Carboxydichlorofluorescein) by the esterases when the oxidation occurs. Carboxy-H2 DCFH-DA
was prepared in 1X PBS and added to the treated cells for 30 min at 37 °C, protected from the
light. After the incubation, cells were washed with 1X PBS and read using a microplate reader
fluorimeter (Labsystems Fluoroskan Ascent).
3.1.12 Confocal Microscopy and Immunocytochemistry
Aβ (25−35) provokes the interaction of chaperones proteins and PD biomarkers. Therefore,
cells were treated with antioxidants compound against Aβ (25−35) insult. After cells were
pretreated for 24 hours with Braz before Aβ (25−35) exposure, they were washed with PBST and
fixed with 4% (PFA) in PBS. Cells were then incubated with a blocking solution (5% normal goat
serum (NGS) and 5% of FBS fetal bovine serum in PBST) for 1 hour on the shaker to eliminate
unspecific binding of the antibodies. After three repeated washes, cells were incubated with
primary antibody overnight at 4 °C diluted in 3% BSA in PBST. The secondary antibody,
conjugated with an Alexa Flour tag, 488, and Texas Red (anti-mouse, anti-rabbit, and DAPI)
(Table 2), was added for 2 hours at room temperature on the shaker. Images were captured using
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an LSM 700 confocal microscope, assisted with Zen 2009 software (Zeiss). For consistency,
images were acquired at a 512-pixel resolution by utilizing a 488 nm laser with a laser power of
5.0, speed 7, averaging 8 and 1.0 Airy Units (AUs). Besides, no further adjustments were applied
in brightness, contrast, or gamma settings.
3.1.13 Statistical Analysis
The study with the SH-SY5Y data was obtained in replicates to demonstrate the
experimental viability and variability between samples; therefore, the data presents the average
with the corresponding standard deviation ± SD. Statistical analysis was performed using a twotailed paired Student's t-test if two data sets were being compared. For the comparison of multiple
data set, a one-way analysis of variance (ANOVA) was used. These tests were performed in Origin
Pro 2018 (academic) software. The critical value of < 0.05 probability was defined as the level of
statistical significance.
3.2

RODENT STUDY BASED METHODS
This section corresponds to the study of a non-constitutive amyloid protein that corrupts

neurons and drives cross-toxic outcomes. The Aβ peptides were infused in the midbrain
(tegmentum) of Lewis rats. All males' rats n=87 underwent stereotaxic surgery, where they
received a unilateral infusion (Figure 9). The experimental groups were divided into different
parameters, such as Aβ (1-42), and Aβ (25-35), and negative vehicle control (DMSO). Fourteen
days following surgery, animals were tested on four behavioral tests sensitive to a diverse degree
of nigrostriatal dysfunction: 1) the adhesive removal test in which animals were tested on their
ability to sense the adhesive stimulus (time-to contact) and remove it (time-to removal) a sticker
on their forelimbs, 2) a locomotor asymmetry test in which rats were required to touch (supported
rears) against a plexiglass wall 3) the ladder test evaluate their skill with limb placement using a
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ladder, and finally 4) the wire hangs, a task was we evaluated their neuromuscular by hanging or
releasing from a wire. All these behavioral tests were performed 3, 6, 9- and 12-months postinfusion (m.p.i). After the end of behavioral testing, every 3 months, brain tissue was collected
and performed immunofluorescence (IF) to determine the extent of TH neurons lesions. We used
the information obtained from the histology to determine any correlation with the result from the
motor behavior (Figure10 ). This study joined collaborations with Lois Mendez, Erick Guerrero,
Stephen Collins, Ariel Schmid, and Daniela Gonzalez.

Figure 9. Representation of the Experimental Treatment Groups and Overall
Timeline
3.2.1

Rodents, Chemicals, and Materials
The following reagents were obtained commercially as high purity reagents (>99%): Aβ

(25-35)(AnaSpec AS-24448) and Aβ(1-42) (Genscript, RP10013). Hexafluoroisopropanol (HFIP)
(ICN15124580), DMSO (S67496), Cytoseal TM-60 (8310-16), and Methanol (A433P-4),
Coomassie Protein Assay Reagent (1856209), Pierce ECL Western Blotting Substrate (32106)
were obtained from Fisher Scientific. Isoflurane was obtained from a University-approved local
veterinary dispensary. Thionine acetate (229840250) purchased from Acros OrganicSodium
pentobarbital (1507002-200MG), Paraformaldehyde (PFA) (P6148-500G), Thioflavin S (T189234

25G), Bovine Serum Albumin (BSA (A2153-10G)) were purchased from Sigma-Aldrich.
Antibodies were obtained from Invitrogen, Abcam, Cell Signaling, Millipore, and Santa Cruz
(Table 2).

Figure 10. Schematic Representation of All the Experimental Processes. (1)
Surgery procedure. (2) Behavioral testing (3) Cellular analysis for histopathology study.
3.2.2

Animals Models
Male (300±50g) Lewis laboratory rats were obtained from Hilltop Lab Animals, Inc. All

animals were pair-housed in ventilated cages under standard housing conditions in an IVC rack
system. The room was in a 12/12h light-dark cycle (dark: 08:00-20:00), at a temperature of 22 +/2°C with a constant relative humidity of 35%. Rats were fed with standard rodent chow and
water ad libitum. Before experiments, rats were habituated for seven days and handled for 5-15
minutes/day for seven consecutive days. All experimental procedures were approved by the
Institutional Animal Care and Use Committee (IACUC) at The University of Texas at El Paso.
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3.2.3

Surgery and Handling
This experiment introduced an amyloidogenic protein into a heterotypic neuronal locus

that does not naturally express Aβ. The rats were anesthetized with the inhalant isoflurane (4% for
induction with 1.5-2.5% maintenance). Next, a unilateral infusion to the tegmentum (midbrain)
area was performed using coordinates from the Paxinos & Watson Atlas, 6th ed (AP -5.4 mm, ML
+/- 2.1mm, and DV-7.7mm from bregma). Once everything was secured correctly with the
stereotaxic apparatus and before receiving the unilateral infusion, rats were given 5-6 mL of saline
s.c., 2.5mg/kg flunixin s.c.
All groups received a 2 µL infusion, at a flow rate of 0.5 µL/min, of the respective
substance at the appropriate concentration. After being placed in the coordinates above, the syringe
was left to sit for 2 min both after being placed in the proper coordinates and after the infusion was
done. After surgery, animals were allowed to recover from the anesthesia. Individual rats were
maintained within separate Plexiglas chambers until fully awake, typically within 2-3 hours before
returning to their home cage with their cage mate. We did the same surgery and treatment with
rats from the same cage. Rats were then monitored 3x daily for at least five consecutive days to
ensure proper recovery. The animals were allowed to recover for fourteen days post-surgery fully,
during which time they will be monitored twice per day. Following these two weeks, animals were
handled for 5-15 minutes and weighed daily. As part of the daily handling routines after the
surgery, animals were assessed for the emergence of a PD phenotype. These include bradykinesia,
postural instability/unsteady gait, and rigidity.
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3.2.4

Behavioral Testing
For all quantified behavioral tests, the experimenter was blinded until the analyses were

complete. These tests are already standardized and are used to evaluate locomotor function postinfusion. All behavioral studies were performed in Psychology, room 220, under the supervision
of Dr. Edward Castañeda. Animals were divided into three infusion groups (vehicle, Aβ25-35, and
Aβ(1-42)) (Figure 9). As seen in this Figure 9, the number of rats available for testing at 9 months
was less in some experimental groups due to attrition or some rats meeting an earlier humane
endpoint. Such data were discarded from further analysis. In addition, evaluating the animals'
health and appearance was performed every other day to monitor animal welfare and behavioral
evolution.
To evaluate Aβ peptides' pathological effects, rodent motor function was determined by
measurements of forelimb use on a vast number of behavioral tests at varying time points during
the study. The order of the tests was randomized and conducted by experimenters who were
blinded to the treatment group. All tests were conducted between 08:00-12:00 in the lights-on
cycle. Rats were previously habituated to the experimenter and testing room. All apparatus was
cleaned with 70% isopropanol in between animals to minimize odor cues. All behavioral tests were
conducted following a protocol previously approved by the Institutional Animal Care and Use
Committee (IACUC) at The University of Texas at El Paso.
3.2.4.1 Adhesive Removal Test (Sticky Dot Test)
The adhesive removal test is a behavioral test designed to assess both paw somatosensory
sensitivity and motor skills.107 The rats' sensorimotor abilities were evaluated by placing small,
circular adhesive stickers (12 mm diameter, round, red glow, removable; Avery®) on the globular
pad of the forelimb paws bilaterally. Two latency measures were recorded: 1) the time to contact
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each stimulus and 2) altogether removing each stimulus from their paw. Trials were discontinued
after 3 minutes. Trials in which one or both stickers fell off before being touched by the animal
were discarded and repeated. This test has been repeated a minimum of 3 times. The values shown
represent the average of the three trials. This test's relevance resembles the so-called "extinction"
task in human patients when neurological disorders are present.108,109 This test was performed at
three different time points to observe the evolution of sensorimotor deficits, if any, in a timedependent manner. Since a unilateral infusion was completed, individual paw performance was
analyzed (contralateral /ipsilateral) to evaluate lateralized hemispheric effects. 107
3.2.4.2 Single Akinesia Test (Cylinder Test)
The forelimb akinesia test, also called the cylinder test, is intended to test for a rat's
independent forelimb to support the body during spontaneous exploration of cylindrical enclosure
walls. This is a standard test of motor function after unilateral lesions.39,110 It was conducted by
placing the rat in a Plexiglas cylinder (height- 30 cm, diameter- 20 cm) and then videotaped for 2
minutes (Figure 10). No habituation to the cylinder before filming was allowed. The test was
performed between 10:00 hours and 16.00 hours. Video recordings were analyzed by an
investigator blind to the treatment group. The number of weight-bearing forepaw contacts on the
wall performed by an independent paw (the left and the right forepaws) was counted up within the
2 minutes session. Only supporting contacts were counted.111
3.2.4.3 Skilled Limb Placement (Ladder Test)
The ladder test is also known as skilled limb placement. Fourteen days following surgery,
animals were weighed daily for five consecutive days. During this time, animals that were found
above or at their average pre-surgery weight were food-restricted by limiting access to their
standard chow food to 1-3 hours daily. Rats were maintained at their 90% body weight but not
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allowed to drop below their 85% average body mass by increasing their access to food for up to 3
hours per day. This food restriction was necessary to perform this test.
This test allows us to measure the motor coordination and execution of movement. At the
same time, a rat crosses a vinyl-coated metal ladder (23 cm wide by 122 cm long with 3 mm
diameter rungs evenly spaced 2.5 cm apart, center to center). Rats were trained until they
demonstrated proficiency in running through the ladder. On the first day of training, rats were
placed in a black Plexiglas goal box (25 cm l by 25cm w by 23cm h) with an open doorway (10.5
cm w by 10cm h) with a food reward (small pieces of Nilla® wafers) inside. After a few minutes,
they were moved to the midpoint of the ladder. Rats quickly learn to cross the ladder and enter the
goal box for food. Subsequent trials involve placing rats at the opposite end of the ladder (i.e., start
position, against a Plexiglas barrier (37 cm by 44 cm). On testing day, rats were placed at the start
position and videotaped until they entered the box. Only trials comprised of continuous forward
progress from start to goal were used for analysis. To prevent injury from falling from the ladder,
a soft cushion (inflated trash bag) was placed below the ladder to allow for a soft landing. Before
placing the rat on the ladder and immediately afterward, the ladder and the box enclosure were
wiped down with 70% isopropyl alcohol. Rats underwent 3 test trials. 112
3.2.4.4 Wire Hang Test
The Wire Hang test seeks to evaluate motor function and deficits in rodent models of CNS
disorders. A simple test of muscle rigidity, i.e., grip release, was used to test impairment and time
to initiate the voluntary release. Rats were placed on top of the vinyl-coated metal ladder (23 cm
wide by 122 cm long with 3 mm diameter rungs evenly spaced 2.5 cm apart, center to center); the
ladder was then inverted such that the rats hung upside-down. The latency of rats to release their
grip and fall off the ladder onto the pillow below was recorded. Rats underwent 3 test trials. 113
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3.2.5

Histological Analysis

3.2.5.1 Tissue Processing
Animals were deeply anesthetized with 100 mg/kg injection (i.p.) of sodium pentobarbital.
Following rat were transcranial perfused with 0.9% normal saline followed by 4% PFA in
phosphate-buffered saline (PBS). Rat brains were collected, cryoprotected in a 30% sucrose
solution, and frozen. The collected tissues were placed in an Ethylene glycol (anti-freeze) solution
for future use. Lastly, frozen tissue specimens were cut at a 30-µM-thick coronal section using the
Leica CM 1950 cryostats. We also performed a second method for different molecular analyses
where rats were euthanized without anesthesia via rapid decapitation and their brains quickly
removed and placed in ice-cold saline.
3.2.5.2 Nissl Staining
Nissl is a well-known technique that stains brain tissue and reveals anatomical parts of the
brain; the solution of thionine acetate stains Nissl bodies. A series of solutions, including water,
100% ethanol, 95% ethanol, 70% ethanol, 50% ethanol, xylene, and thionine, were used for this
process (Table 1). First, the tissues were dehydrated to be compatible with xylene, which removes
fat from the tissue. When the tissues had been dehydrated, they were gradually rehydrated to be
stained with thionine. Finally, after the tissues were stained, they were dehydrated and finally
sealed with Cyto-seal TM-60. Images were taken using an inverted fluorescence phase microscope
(Keyence BZ-X710) with a 5x objective.
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Table 1. Nissl Staining Procedure
Time
3 min
3 min
3 min
3 min
3 min
3 min
3 min
3 min
5 min
30 min

Solution
Di Water
50% EtOH
70% EtOH
95% EtOH
95% EtOH
100% EtOH
100% EtOH
100% EtOH
Xylene 1
Xylene 2

Purpose
This dehydrates the tissue so
that it can be compatible with
Xylene, which removes fat from
the tissue

2 min
2 min
2 min
2 min
2 min
2 min
2 min
2 min
2 min

Xylene 1
100% EtOH
100% EtOH
100% EtOH
95% EtOH
95% EtOH
70% EtOH
50% EtOH
Di Water

This gradually rehydrates the
tissue so that it can be stained
with the Thionine/Nissl

8-20 dips

Thionine

Stains the Tissue

20 dips
20 dips
20 dips
3 min
3 min
3 min
3 min
3 min
3 min
3 min

Di water
50% EtOH
70% EtOH
95% EtOH
95% EtOH
100% EtOH
100% EtOH
100% EtOH
Xylene 1
Xylene 2

Dehydrate tissue so that it is
compatible with the mounting
medium DPX

3.2.5.3 Immunofluorescent Labeling and Colocalization Analysis
Immunofluorescence (IF) was performed with some modifications as described in the
Kyuseok method paper.114,115 After the tissue sections were selected using the Watson Atlas with
Nissl staining to ensure the whole brain's representation and serial sections were fluorescently
labeled. Primary antibodies used and the dilutions are detailed in (Table 2). Slides were first
removed from the cryopreservative solution and rinsed with PBS 3 times for 5 minutes every wash.
Slides were then blocked in 0.25% goat serum and 0.1% Triton X-100 solution for 2 h. Slides were
incubated in primary antibodies overnight at 4 °C. For IF, the following day, tissues were washed
as previously described, then incubated with Alexa Fluor-conjugated secondary antibodies. Slides
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were incubated for 2 hours at room temperature on a shaker protected from light. After incubation
with secondary antibodies, sections were washed, mounted onto glass slides, and sealed using
sodium bicarbonate mounting media. Slides were visualized using a confocal microscope, LSM
Zeiss 700, with a 20X and 40X magnification.
Table 2. Antibodies and Dilutions
Primary Antibodies

Clonality

Dilution

Host

Tyrosine Hydroxylase (TH)

M

1:5000

Mse

Invitrogen

NeuN

M

1:1000

Rb

Abcam

Phosphorylated a-synuclein at Ser
129 (PSer129)

M

1:1000

Rb

Thermo Fisher

*Ubiquitin

M

1:500

Mse

a-synuclein

M

1:200

Rb

Protein Disulfide Isomerase (PDI)

M

1:200

Mse

Secondary Antibodies

Dilution

Anti-Rabbit

Cell Signaling and
Technology

Alexa Flour 488
1:2000

Alexa Flour 568

1:300

Company

*Formic acid treatment 88%

Conjugate

Anti-Mouse
Anti-Rabbit

Antigen retrieval

Texas Red

Company
Cell signaling and
Technology
Abcam

Dye

Dilution

Company

Thioflavin S

1%

Thermo Fisher

Dapi

1:1000

Gift

Key : IF, immunofluorescence M, monoclonal, Mse, mouse, Rb, rabbit

Thioflavin-S Staining: Thioflavin-S (ThS) is one of the most significant histological
fluorescent dyes used to detect any form of amyloids. This dye binds specifically to the
characteristic of β-pleated sheet conformations of any amyloids.116 Following secondary antibodies
incubation, tissues were mounted and then co-stained with 1% aqueous ThS for 8 min at room
temperature. Afterward, sections were washed twice with 80% ethanol for 3 minutes, then washed
again for 3 minutes with 95% ethanol, followed by 3 washes with distilled water. The slides were
then mounted onto glass slides and sealed using sodium bicarbonate mounting media. Imaging of
the tissue sections was taken with a confocal microscope, LSM Zeiss 700, with a 40X
magnification (Table 2 ).
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Tyrosine Hydroxylase, Cell Count, and Colocalization Analysis: Tyrosine hydroxylase
(TH) is a marker for dopaminergic neurons. For this project, we assessed the quantification of
dopaminergic (DA) neuronal loss. All desired tissues were rinsed with PBS with 0.1% (v/v)
Tween-20 (PBST). Tissues were incubated in blocking solution for at least two hours prior to being
stained with anti-tyrosine hydroxylase primary antibody and a corresponding secondary antibody
conjugated with a fluorescent tag. Sections were mounted and left to air dry overnight (protected
from light). Imaging of the tissue sections was taken with a confocal microscope, LSM Zeiss 700,
with a 20X magnification. The total number of TH-immunoreactive dopamine neurons was
estimated using the NIH ImageJ software after images were acquired. The plugin was downloaded
from ImageJ.nih.gov website: download FIJI: https://imagej.net/Fiji#Downloads. Counting with
some modifications was performed as described. The parameters used in this stereological
assessment were as follows: Grid size1:6,800µM2, calculating frame 50X50 µM, selecting the
SNpc, and adjusting threshold as needed.
Colocalization Analysis: Colocalization was performed as described using the opensource plugin for ImageJ called Ez Colocalization.117 Quantitatively, colocalization was measured
by applying specific algorithms that calculate the degree of colocalization coefficients. One of the
algorithms used for measuring the degree of colocalization was the Pearson's Correlation
Coefficient (PCC). PCC measures the pixel-by-pixel covariance between the intensities distributed
in the two images. For example, between ThS (green) and Pα-syn (red) in this study. To
qualitatively measure amyloid aggregates and their colocalization with Pα-syn, we report the
signal intensities for both probes. The range of both coefficients goes from −1 to +1 for the PCC.
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Additionally, colocalization was calculated with the algorithm based on Mander's overlap
coefficient (MOC). Mander indicates the overlap of the signals (co-occurrence) and represents the
true degree of colocalization. It estimates the contribution of a single color in the colocalized area
to the total colocalized fluorescence within the image, giving two values (M1 and M2). Graph M1
defined the contribution of the fraction of the red channel to the colocalized area in compartments
containing the green channel. By contrast, the M2 graph describes the contribution of the green
channel in compartments containing the red reporter channel. 117–121 The range of both coefficients
goes from 0 to +1 for the MOC. This means that a value of +1 is a perfect correlation, −1 is a
perfect but negative correlation, and 0, which denotes the absence of a relationship.122
3.2.6

Detecting Proteins of Interest by Western Blot
The first step was to perform protein extraction from the striatum. Brains were rinsed with

PBS, and total proteins were extracted using RIPA buffer containing protease and phosphate
inhibitors. Protein concentrations were determined by Bradford assay for all immunoblot assays.
Equal amounts of protein (25μg) were separated by 10% polyacrylamide gel electrophoresis
(PAGE) and transferred to polyvinylidene difluoride filter membranes (PVDF). The membranes
were blocked using blocking buffer (5%, w/v, dried skimmed milk in Tris-buffered saline, and
0.1% Tween 20, with a pH 7.4, followed by incubation with antibodies of protein interest in 3%
BSA in PBS. Then, by incubation with horseradish peroxidase (HRP)-conjugated goat anti-rabbit
in blocking solution. Chemiluminescence was used according to the manufacturer's instructions.
Actin was used for housekeeping, loading protein control.
3.2.7

Statistics for Rodent Study
The number of samples analyzed in this study is represented as "n"; likewise, the p-values

for all results are found within the figure legends. A one-way ANOVA was used if means between
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groups were normally distributed. However, if data did not follow the normality test, then data
were evaluated using non-parametric analysis (multifactorial Kruskal/Wallis one-way ANOVA),
followed by post hoc pairwise comparison Tukey's test. Results presented as mean/SEM were
processed using the Origin Pro 2018 (academic) software. The critical value of p < 0.05 probability
was defined as the level of statistical significance.
Behavioral data compared vehicles to Aβ injected animals using the Cox proportional
model. Cox regression implements the proportional hazards model or duration to event model,
designed to analyze time until an event. One or more covariates are used to predict a status (a
contact, removal, a fall from wire) variable. In the estimated Cox models below, if the hazard ratio
(exp(coef)) is below 1.0, with a higher covariate, the less the rate of a long time to the event
occurring (increasing predicted survival (removal, falling) times). The more the hazard is above
1.0, the more the variables increase the rate of a long time to the event occurring (ex., removal=1:
diminishing predicted survival times).
The best form of the model is indicated by the lowest Akaike's Information Criterion (AIC)
and likelihood ratio test (LRT). p-values are reported for specific parameters in the model. The
cylinder and ladder tests were both analyzed by a generalized linear mixed-effect model. The
model association between the number of paw touches, number of slips, and time was examined
using a Poisson generalized linear mixed-effect model (R version 3.2.2.). The Group and Side were
included in the mixed model as fixed effects, and the rats were modeled as a random effect. We
ran a separate analysis for a month as a continuous or categorical variable. A p < 0.05 was
considered statistically significant. In the adhesive removal test, we calculated the non-treated to
treated ratio and removed the outliers using the standard deviation of the data distributions. We
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assumed an outlier when the value was more than 2 times the standard deviation of the mean.
Statistical analysis was based on collaborations with Amy Wagler and Soyoung Jeon.
3.3

CAENORHABDITIS ELEGANS BASED METHODS

3.3.1

(C. elegans ) Culture and Maintenance
Strains Bristol N2, wild type (WT), was generously provided by the link's Lab at the

University of Colorado, Boulder. The strains BZ555 (Pdat-1:GFP; expressing green fluorescent
protein (GFP) represented in the dopaminergic neurons) were purchased from the Caenorhabditis
Genetics Center (CGC), University of Minnesota, USA. Each test began with synchronized L1
larvae, obtained by 1M NaOH and 6% RICCA sodium hypochlorite solution to harvest the eggs.
Worms were cultured on a standard nematode growth medium (NGM; 0.3% (W/V) of NaCl, 1.7%
(W/V) agar, 0.25% (W/V) peptone, 1M CaCl2, 1M MgSO4, 1 M KPO4, 5mg/mL cholesterol) at
20°C, seeded with Escherichia coli strain OP50 as a food source until they reached the stage
needed. The E.coli OP50 grew in super optimal broth media (SOB media) overnight on a shaker
incubator at 37°C. All the strains were maintained in the incubator at 20ºC. For some tests, worms
were transferred at room temperature to be monitored and avoid overcrowded plates. We use
Worm book.org for all procedures. 103
3.3.2

Freezing and Recovery of C.Elegans from Stocks
C. elegans strains were frozen using Soft Agar Freezing Solution (0.6% (W/V) NaCl, 0.7%

KH2PO4, 30% (V/V) glycerol, 1 M NaOH, 0.4 %(W/V) agar, H2O). We used worms of 2-3
medium NGM plates with many freshly starved L1and L2 animals. Worms were washed off with
0.6mL of S Buffer ( 0.05 M K2HPO4,0.05KH2PO4, 5.85g/L NaCl) for each vial that was going to
be frozen. The liquid was collected in a covered sterile falcon tube and placed on ice for 15
minutes. After adding an equal volume of Soft Agar Freezing Solution, the worm suspension was
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mixed well and aliquoted 1 mL of mixtures into 1.8 mL cryovials labeled with the strains name
and date. The cryovials were packed in a Styrofoam box to achieve a slower freezing rate. The box
was placed first at -20ºC for 30 minutes and then transferred in a -80ºC freezer overnight. The
subsequent day vials were moved to their permanent freezer locations. An aliquot of the frozen
mixture from one of the vials was thawed and plated as a tester to check there were surviving
worms.103
3.3.3

Percent Survival on Paraquat Sensitivity
For lifespan measurements upon CQDs and Paraquat insult, aged-synchronized WT and

BZ55 L1 larvae were transferred to pre-seeded NGM 60mm Petri dishes with different
concentrations of Paraquat and Citric Acid N-Doped CQDs. The plates were previously prepared
by adding Paraquat to the NGM while stirring at a final concentration of 1mM-4mM. The process
was repeated with all treatment (CQDs) and control (no pesticide or CQDs). We also add the 5fluorouracil at a final concentration of 50µM. The 5-fluorouracil is a DNA replication inhibitor
commonly used to sterilize c. elegans to maintain a synchronized aging population and avoid being
contaminated by their progeny. Each preparation was poured into 60mm Petri dishes and was
allowed to be solidified and dried overnight. The next day plates were seeded with 50µL of E. coli
OP50, allowing the bacteria to be dried overnight.
To maintain statistical power, the number of worms at the starting process was higher than
the number of worms intended; approximately 15-20 worms for each concentration were seeded
and incubated at 20ºC. The survival of worms was noted daily until all worms had died. Worms
were scored as dead if they failed to respond to repeated prodding on the head with the tip of a
platinum wire; dead animals were removed from the plate. A graph was generated by calculating
the percentage of animals surviving at each observation time point.
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3.3.4

Evaluation of the neuroprotectant effect of Citric Acid CQDs
To examine the effect of Paraquat and the CQDs on DA neurodegeneration, we used GFP-

tagged transgenic strains such as the BZ555. Age-synchronized L1 larvae were incubated
performed in a 24-well plate with 250 µL reaction volume containing approximately 200 worms
(20 µL of larva suspension) Paraquat at (2mM) dissolved in DI H2O2, the various concentration of
CQDs diluted in K-medium (32mM KCl0.3% (W/V) NaCl in DIH2O). Fresh overnight grew a
culture of E.coli OP50. The worms were incubated first in the CQDs at room temperature for 24
hours in slow, constantly shaking. Passed the 24 hours ours, worms were then washed with M9
buffer ( 2 g/l KH2PO4, 5 g/l NaCl, 6 g/l Na2HPO4, 1 mM MgSO4). The group of worms that were
going to be insulted with Paraquat was incubated in a 24-well plate with 250 µL reaction volume
for 72 hours at room temperature in the shaker. After the incubation, worms were washed with M9
buffer and transferred to the agarose pad (2% agarose in DIH2O2) prepared on a glass slide
(Illustration 1).

Illustration 1. Worm Agar Pad
Worms were immobilized on the agar pad with sodium azide solution (100mM). The
worms were observed under a fluorescence microscope (Zeiss 700) (excitation wavelengths 455
nm to 488 nm). The effect of Paraquat on dopaminergic neurons was considered to exhibit neuronal
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loss when one of the neurons from the head revealed degeneration. This was evaluated based on
the loss of green fluorescence. BZ555 possess eight neurons located in the anterior region,
classified in pairs of two anterior deirid neurons (ADE), two dorsal cephalic neurons (CEP), which
are postsynaptic to the ADE neurons, and two ventral CEPs that are not postsynaptic to the ADEs
and two posterior deirid neurons (PDE) located posteriorly. We only observed the effect on the six
of the head.123 We quantify the green intensity of the neurons and the number of worms exhibiting
degeneration. The percentage of neurodegeneration was calculated as follow:

% of neurodegeneration=

3.3.5
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Statistical Analysis
The study with the SH-SY5Y and the C. elegans data were obtained in replicates to

demonstrate the experimental viability and variability between samples; therefore, the data
presents the average with the corresponding standard deviation ± SD. Statistical analysis was
performed using a two-tailed paired Student's t-test if two data sets were being compared. For the
comparison of multiple data set, a one-way analysis of variance (ANOVA) was used. These tests
were performed in Origin Pro 2018 (academic) software. The critical value of < 0.05 probability
was defined as the level of statistical significance. Lifespan analyses were performed using the
Online

Application

for

the

Survival

Analysis

of

Lifespan

Assays

(OASIS;

http://sbi.postech.ac.kr/oasis/introduction/).124 Mean/Median lifespans were compared using the
log-rank test, and mortality at more specific time points was compared using Mann-Whitney U
Test.
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Chapter 4
Testing the Neuroprotective Effect of Brazilin on Amyloid Protein-Induced Pathology

4.1

INTRODUCTION
One of the main features of neurodegenerative disorders is the presence of amyloidogenic

disease proteins. These include Aβ and Tau in AD, α-Syn forming Lewy bodies (LBs) in PD.125,126
These proteins are known to participate in the formation, accumulation, and deposition of toxic
misfolded aggregates.127 In NDs, amyloidogenic proteins have similar characteristics to prion-like
proteins and can spread via a cell-to-cell transmission (Figure 8).79 Consequently, this leads to
provoke chemical modification of proteins, cytotoxicity, oxidative stress, and the activation of
different cellular pathways. Numerous studies have demonstrated the convergence between AD
and PD pathologies since post-mortem tissue of AD patients exhibit significant amounts of Aβ
and α-Syn and Tau. Clinically, it has been observed that patients with PD have present symptoms
of dementia, a disease called PD with dementia or PDD. Additionally, Aβ aggregates are copathological with TDP-43 cytoplasmic inclusions in over 50% of the cases and with α-Syn over
40% of the cases. Conversely, α-Syn pathology in LBs has been found to co-occur with Aβ
pathology (>80% of the cases), with NFT and NT at Braak stage II (over 50% of cases) and with
TDP-43 pathology (over 30% overlap).87,89,128–131
On the other hand, natural plant extracts have been used to target amyloid-dependent
proteinopathies for many years due to their ability to decrease free radical damage by inhibiting
and dissolving amyloid fibrils. In this study, we explore the effectiveness of Brazilin, a compound
obtained from the wood plant Caesalpinia sappan that can inhibit the aggregation of Aβ and αSyn and mitigate other pathological features of AD and PD. Previous studies have suggested that
Brazilin has a potent inhibitory effect against Aβ (1-42) neurotoxicity as a phenolic antioxidant.132
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Here, we examine its role in preventing Aβ-induced toxicity, aggregation and in modulating the
Aβ dependent aggregation pathway of other amyloid proteins (Figure 11). This project was based
on joining collaboration with Mahesh Narayan, Ph.D. Lois Mendez, Erick Guerrero, Alejandra
Gomez, and Armando Varela, Ph.D.

Figure 11. Brazilin Mechanism of Action. Brazilin as a protective agent from
oxidative stress and apoptotic cell death. Figure reproduced from reference. 76
4.2

RESULTS

4.2.1

Dynamic Light Scattering (DLS)
Figure 12 shows the size of Aβ (25−35) in solution using dynamic light scattering. The

method used for Aβ preparation and analysis is presented in chapter 3, materials and methods
(3.1.2 and 3.1.3). In accord with previous studies, Aβ (25−35) was found to be (1.0−1.5 nm) at a
concentration of 100 μM, beyond which it was found to form aggregates immediately after
preparation. The two small peaks to the left represent the oligomeric size distribution, whereas the
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third peak of the graph to the right corresponds to the formation of protofibrils.22,133 DLS was done
in collaboration with Erick Guerrero.

Figure 12. Size of the Aβ Oligomer. Graph depicts the oligomeric size
distribution intensity with a diameter of ∼1.0–1.5 nm. Figure reproduced from reference 76
4.2.2

1,1-Diphenyl-2-picrylhydrazyl (DPPH) Assay
In order to determine the specific antioxidant activity of Brazilin. The assay is easy and

economical for evaluation the radical scavenging activity of natural antioxidant extracts. We tested
its free radical scavenging capacity by observing the diminution of UV absorbance maximum of
the DPPH radical (Figure 13). DPPH is stable nitrogen centered composed of free-radical solution
molecules. DPPH produces a violet color and fades to yellow color in the presence of antioxidants.
134

Brazilin in DMSO at concentrations 2.5 and 5 μM was able to quench the DPPH radical

absorbance. Brazilin was capable of scavenging free radicals and reducing the reactive oxygen
species stress of DPPH (Figure 13). The percentage of DPPH radical inhibition was found to be
65.7% at 2.5 μM and 79.5% at 5 μM, using ascorbic acid as a reference.135 An efficient antioxidant
extract is considered due to the antioxidant concentration and the reaction time of that scavenging
reaction to reach the plateau. This in vitro assay demonstrates that Brazilin exhibited a high free
radical scavenging ability, which could be used to prevent the progression of diseases caused by
free radicals, such as NDs and cancers.
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Figure 13. Brazilin Radical Scavenging Activity. Graph shows the free radical
scavenging activity of Brazilin at 2.5 and 5.0 μM. Brazilin was able to decrease the absorbance
obtained from the free radical solution, 1,1-diphenyl-2-picrylhydrazyl (DPPH). Figure
reproduced from reference.76
4.2.3 Determination of the Cytotoxicity Concentration of Brazilin
We used the cytotoxicity assay to define the concentration needed to kill 50% of the SHSY5Y cell population. The profile of Brazilin (1%v/v DMSO) in the cell line was established by
measuring the percentage of cell death as a function of Brazilin (Figure 14). After utilizing the
unbiased dose-response graph, concentrations that were not cytotoxic to the SH-SY5Y cell line
were used for further experiments. There was no difference between untreated or vehicle control
and Brazilin treatment on SH-SY5Y cells up to a concentration of 5 μM Brazilin which was then
used to continue with the rest of the study (Figure 14 A). Figure 14 B & C represent the live cell
and dead cells of positive and negative controls.
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Figure 14. Brazilin Dose-Response Curve Using SH-SY5Y Cells After 24
Hours of Exposure. Panel (A) Shows the cytotoxicity effect at different concentrations of
Brazilin. (B, C) Representative images of DMSO and H2O2 as the positive and negative controls
using the nuclear dye (DAPI-blue) and membrane impermeant dye (propidium iodide-red),
respectively, to assess Brazilin cytotoxicity. Data are mean values± SD from triplicates;
differences were established using student’s t-test (p < 0.05, p < 0.001). Figure reproduced from
reference. 76
4.2.4

Determination of the Cytotoxicity Effect of Aβ Variants
We also measured the toxicity effect of scrambled, reversed (35-25), and WT (25–35) Aβ

variants. Fresh peptides were diluted to different concentrations (1-20µM ) and incubated at room
temperature for 1 hour before being added to the cells. Cells were incubated with the peptides for
24 hours prior to the reading. The method used for cytotoxicity is presented in chapter 3, materials
and methods (3.1.8). The result revealed that WT (25–35) Aβ demonstrated potent toxicity than
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the scrambled and reversed Aβ (35-25) peptide simultaneously and under similar preparation
conditions (Figure 15). This result revealed that scrambled and reversed peptides were less
effective in causing neurotoxicity than the vehicle (H2O). Previous studies used the reversed and
scrambled peptides as a control since these peptides lack oligomeric species. Therefore, they
cannot form self-assemble, which explains why these two variants are not cytotoxic to SH-SY5Y
cells. 136

Figure 15. Cytotoxicity of Amyloid-β Variants. Cytotoxicity of scrambled,
reversed (35-25), and WT (25–35) Aβ variants after 24 hours of treatment. Data are mean values
± SD; differences were established with Student’s t-test. Data are mean values± SD from
triplicates; differences were found using student’s t-test (p < 0.05, p < 0.001).

4.2.5

Neurotoxicity Effect of Aβ (25–35) in SH-SY5Y Cell Line
Aβ (25–35) was freshly prepared, as previously mentioned in chapter 3 (3.1.8). The

cytotoxicity of Aβ (25–35) was independently evaluated 24 hours after insulting. The results reveal
a smooth, dose-dependent increase in cytotoxicity (Figure 16 A). Evident changes in morphology
are observed between 20 and 50 μM of the added peptide, 24 hours after incubation provoked by
the oligomeric form of Aβ (25–35) (Figure 16 B-C). Previous studies have shown that aggregated
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form of Aβ (25–35) is toxic and leads to activation of different intracellular pathways, elevates
intracellular oxidative stress, and induces mutation to some chaperone proteins.31
4.2.6

Brazilin Protect SH-SY5Y From Aβ (25–35) Toxicity
As observed in the previous graphs, Aβ (25–35) induced toxicity to the SH-SY5Y. Using

previous methods and conditions (chapter 3 3.1.8), we evaluated the effect of Brazilin as a
prophylactic agent against the Aβ (25-35) toxicity. Our results suggest that Brazilin can protect
cells from the cytotoxic effects of Aβ (25–35) (Figure 17). Interestingly, our results indicate that
the protective effects of Brazilin are observed only at a concentration of 5 μM show a statistical
difference of ( p= 0.0018) with the Aβ (25–35) 20µM treated group. It has been proposed that the
protective effect of Brazilin against Aβ mediated toxicity is due to the antioxidant and inhibitor
activity. Previous studies have suggested that Brazilin inhibits the fibrinogenesis of Aβ and thus
decrease cytotoxicity.137
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Figure 16. Identification of Amyloid-β (25–35) Effect After 24 Hours. (A)
Cytotoxicity of Aβ (25–35) at different concentrations after 24 hours of treatment. (B–D) Cell
morphology of the SH-SY5Y cell line after 24 hours treatment of Aβ (25–35). Images were
captured using live-cell microscopy, as indicated in embodiments; each scale bar represents 20
μM distances. Data are mean values ± SD; differences were established with Student’s t-test
compared to the vehicle groups. Figure reproduced from reference. 76
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Figure 17. Brazilin Protects Amyloid-β (25–35) Toxicity. Cytotoxicity of
Brazilin shows a protective effect against Aβ (25–35) after 24 hours of treatment. Data are mean
values ± SD; differences were established with Student’s t-test. Figure reproduced from
reference. 76
4.2.7

Role of Brazilin in the Interaction of α-Synuclein and PDI Aggregation
We tested whether Brazilin was able to maintain homeostasis under Aβ (25–35) toxicity.

When SH-SY5Y cells were treated with 20 μM Aβ (25–35), this increased expression of the
oxidoreductase chaperone compared to that of the untreated and vehicle controls due to cellular
stress (Figure 18). Conversely, our results indicated that SH-SY5Y cells were pre-treated with
Brazilin (2.5 and 5 μM) for 1 hour, followed by the addition of Aβ (25–35) and subsequent
incubation for 24 hours at 37 °C. Brazilin diminished the impact of the Aβ peptide on PDI (Figure
18 A) expression levels. Both concentrations of applied Brazilin had statistically significant
impacts (p 0.001) when compared with the controls. Our results demonstrated the ability of
peptide Aβ (25–35) to upregulate the levels of α-Syn in SH-SY5Y cells (Figure 18 B). However,
unlike with PDI, the presence of Brazilin does not attenuate the α-Syn level at any concentration.
The immunocytochemistry assay is detailed in chapter 3 (3.1.11).
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Figure 18. PDI and α-Synuclein Overexpression in SH-SY5Y Cells. Graphs
show the mean intensity of PDI and α-Syn in the cell upon treatment. (A) Untreated (B) Aβ (25–
35) at 20µM, (C) Brazilin at 2.5 µM, (D) Brazilin at 2.5 µM + Aβ (25–35), (E) Brazilin at 5 µM,
(F) Brazilin at 5 µM+ Aβ (25–35), (B,D,E) Confocal microscopy images reveal the presence of
aggregates in the cell (white arrows). All treatments were immunostained with the nuclear
counterstain, DAPI (blue), PDI (green), and α-Syn (red). Data are mean values ± SD;
differences were established with Student’s t-test, with p <0.0001. Images were obtained in a
confocal microscope 20X objective; scale bar measures 20 μM and quantified using LSM Zeiss
software (Zen 2009). Figure reproduced from reference. 76
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4.2.8

Impact of Brazilin Against Aβ (25–35)-Induced Apoptosis
Aβ (25–35) insult may lead to apoptotic cell death.138 Our study examined whether Brazilin

at 2.5 and 5.0 μM conferred neuroprotection by mitigating cellular apoptosis and necrosis. We
observed batch-to-batch variations in the cytotoxic potential of Aβ. Therefore, in this experiment,
we used Aβ (25−35) 50 μM instead of 20 μM as used previously. The bars graph ( Figure 19)
represents the cells treated with Brazilin at 2.5 and 5 μM alone and with Aβ 50 μM. Green bars
represent the percentage of apoptotic cells death, which is expressed as the sum of the lower-right
quadrant (early apoptosis) and the top-right quadrant (late apoptosis) (Figure 19 A). Cells
positive to PI and negative to Annexin V-FITC are represented as gray bars, defined as the necrotic
cell subpopulation. The results indicate that 50 μM of Aβ (25–35) induces apoptosis (statistical
significance was found when the DMSO control, 50 μM of Aβ (25–35), and 2.5 μM Brazilin + Aβ
(25–35) treatment conditions were compared). Brazilin at both 2.5 and 5.0 μM was able to protect
the cells from 50 μM of Aβ (25–35)-induced apoptotic cell death. Cells treated with 100 μM of
H2O2 were used as the positive control, in which an increase in early, late apoptosis, and necrosis
was observed. The details of the apoptosis and necrosis assay are available in chapter 3 (3.1.9).
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Figure 19. Analysis of Brazilin Against the Apoptosis Induced by Aβ . Cells
were double-stained with PI and Annexin V-FITC and then analyzed by flow cytometry. The
graph panel in (A)Shows the apoptotic death induced by Aβ (25–35) in 50 μM. (B–I)
Histograms of untreated cells, vehicle, 100 μM H2O2, 50 μM Aβ, and Brazilin treatment for 24
hours; each bar represents a triplicate measurement, and the mean values ± SD; differences were
established with Student’s t-test with a p <0.05. Figure reproduced from reference. 76
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4.2.9

Determination of the Apoptotic effect of Aβ variants
It is known from a previous study that Aβ induces mitochondrial-dependent apoptotic cell

death. This effect may be due to the regulation of cellular redox potential involving oxidative stress
exerted by the Aβ peptide. In our study, we wanted to demonstrate the apoptotic effect produced
by the oligomeric form of Aβ variants (scrambled, reversed 35-25, and WT 25-35) at a
concentration of 50µM. This result indicated the ability of WT Aβ (25-35) to exert apoptotic death
compared with non-treated vehicles and with the scrambled and reversed variants (Figure 20 ).
This is consistent with the results from cytotoxicity of the Aβ variants (Figure 15), which suggest
that only the peptide WT-Aβ (25-35) oligomers could form toxic species.

Figure 20. Apoptosis Effect of Amyloid-β Variants. Cells were stained with
Annexin V-FITC. The graph shows the apoptotic death induced by Aβ variants scrambled,
reversed (35-25), and WT Aβ (25–35) at a concentration of 50 μM. Bar graph represents a
triplicate measurement, and the mean values ± SD; differences were established with Student’s ttest with a P-value <0.05.
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4.2.10 Brazilin Inhibit Lysozyme Fibrillation
In vitro study uses the known hen-white Lysozyme as a model of the fibril-forming
protein. Fibril presence was assessed by Thioflavin T (ThT) assay, presented in detail in chapter 3
(3.1.6). We tested whether Brazilin can inhibit protein fibrillization. Figure 21 indicates that the
control fluorescence intensity (lysozyme fibrils alone) is greater than when Brazilin was
introduced at the start of the lysozyme fibril-forming process. The reduction in the fluorescence
intensity suggests that Brazilin (5 μM) mitigates the formation of amyloid-like fibrils in proteins.

Lysozyme
Brazilin 5µM

Figure 21. ThT Fluorescence Inhibition of the Lysozyme Aggregation by Brazilin 5 μM.
Figure reproduced from reference. 76
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4.3

DISCUSSION
This study aims to investigate whether Brazilin, a potent antioxidant, and the natural

inhibitory extract were able to reduce the neurotoxicity induced by Aβ (25-35) effectively. Aβ
(25-35) peptide is a by-product of the Aβ 1-40/42 peptide, which retains the toxicity of the fulllength variant and has a similar ability to aggregate.31 Since the oligomeric form of Aβ (25-35) is
thought to be toxic species; we first evaluated if we obtained oligomers after preparation, which
was corroborated by the first two peaks presented in the DLS study. In this study, we wanted to
test the toxic species of Aβ that cause oxidative stress, cellular dysfunctions, and eventually cell
death. Therefore, it was crucial to obtain the oligomeric form of the peptide. Previous studies have
demonstrated the effect of Brazilin in treating multiple diseases, such as tuberculosis, diarrhea,
dysentery, skin infections, and anemia.139 Brazilin, a red dye obtained from the Sappan wood
(Caesalpinia sappan), has been used because it possesses a variety of biological activities, such as
antioxidant, anti-inflammatory, anti-tumor for the treatment of many human diseases, including
NDs. Brazilin has been used for its anti-Alzheimer’s and anti-Parkinson activity when it was
effectively reduced and inhibited the cytotoxicity and formation of α-Syn and Aβ aggregates.140
Our study revealed the powerful antioxidant capability of Brazilin when it was able to
reduce the free radicals present in the DPPH solution. Brazilin did not present toxicity in the treated
cells at different concentrations for 24 hours. We also demonstrated the ability of Brazilin to
protect SH-SY5Y cells against Aβ (25-35) toxicity. The concentrations of 2.5 and 5 µM of Brazilin
could protect the cells against the oxidative stress exerted by the peptide. Previous studies have
suggested that Brazilin plays a role in remodeling mature fibrils of Aβ into a more non-functional
structure. This is consistent with the result obtained in the ThT assay where Brazilin at 5µM was
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able to reduce the fluorescence intensity of Hen egg-white lysozyme. These two results support
the idea that Brazilin can inhibit fibrillogenic and decrease cytotoxicity.
It was interesting to determine the link between the Aβ structure of various Aβ variants
and their toxicity effect in the SH-SY5Y cells line. We used the reversed Aβ (35-25) peptide, the
scrambled form of Aβ, and the Aβ (25-35) to address their toxicity effects. Our result revealed that
only the Aβ (25-35) formed aggregates and behaved as an amyloidogenic protein with neurotoxic
characteristics. However, the scrambled and reversed peptides do not possess self-assembly
property and thus lack oligomeric species non-neurotoxic to the cells. This result was consistent
with the cytotoxicity assay of all three variants and apoptosis. Only the Aβ (25-35) oligomers
represent the toxic and apoptotic cell death entity out of three. The mechanism by which Aβ (2535) insult resulted in causing cellular death through apoptosis signals was tested when 50 µM of
this peptide was compared to the vehicle group, which was found to be statistically significant (P
< 0.0001) when tested with the Annexin V-FITCS.
Previous studies have also reported that exposure of Aβ (25-35) at a concentration of 50µM
and for more than 24 hours induces apoptosis morphological alteration, an increase of apoptotic
pathway, and neuronal cytotoxicity in a concentration-dependent manner. It is suggested that the
elevated production of reactive oxygen species (ROS) by Aβ insult may cause phosphatidylserine
externalization presented as late apoptotic death. This concluded the idea that Aβ (25-35) induces
toxicity via apoptosis. However, the same condition also tested necrotic cell death, resulting in
necrosis in the treated groups; it seems that Aβ (25-35) lacks necrotic death. When the cells were
pre-treated with the antiapoptotic and antioxidant Brazilin at a concentration of 2.5µM, a protective
activity was observed in the combo treatment compared with Aβ (25-35) alone (P=0.0093).
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Finally, this study determined that Brazilin can ameliorate Aβ-induced apoptosis and necrosis of
neuronal cells. 31,141
Aβ (25–35) is known to disrupt cellular homeostasis and the solubility status of proteins.
These include PD-associated proteins α-Syn and chemical mutation of protein disulfide isomerase
(PDI).31,36 This was tested by immunocytochemistry. Expression of PDI was higher in the Aβ (2535) group compared to the group of cells that were pre-treated with Brazilin at 2.5 and 5 µM (P
<0.0001). The mechanism by which Aβ (25-35) causes aggregation is due to the endoplasmic
reticulum (ER) stress-induced peptide, which provokes post-translational modification ( PTMs) of
PDI and α-Syn. However, in this study, we did not observe differences in the α-Syn expressions
across the groups, which does not support results observed in other studies where α-Syn was found
to interact with Aβ (25-35).
4.4

CONCLUSION
This study demonstrates that the natural compound Brazilin can mitigate the neurotoxicity

induced by the oligomeric form of Aβ (25−35) peptide. The phytochemical Brazilin's possess
antiapoptotic, antioxidant, anti-inhibitor, and anti-inflammatory characteristics, a polyphenolic
compound extracted from C. sappan. Our results reveal that low concentrations of Brazilin can
reduce oxidative stress, protect cells from Aβ toxicity, maintain cellular homeostasis, and inhibit
protein aggregation of amyloidogenic proteins, such as Lysozyme. DPPH assay confirmed that
Brazilin was a potent antioxidant that was able to scavenge free radicals. ThT fluorescence assays
established the inhibitory effect of Brazilin on its amyloid-forming trajectory.
Additionally, cell viability assays reveal that Brazilin maintained cell homeostasis when
co-incubated with Aβ (25−35). Brazilin not only protects cells from the formation of aggregates
but also mitigates cellular apoptotic and necrotic death. Finally, the approach investigated in this

66

study will help develop a comprehensive understanding of the cross-toxic origins promoted by
amyloidogenic proteins. Therefore, Brazilin can be considered a potent drug with potential features
in inhibiting amyloid accumulation, which may be beneficial to the treatment of AD and PD. In
conclusion, this work is a stepping stone to furthering our understanding of the neurometabolic
intermediates involved in cross-pathologies and provides a platform to test prophylactics that may
eventually advance/improve therapeutic outcomes.
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Chapter 5
New Rodent Model for the Study of Neurodegenerative Disease

5.1

INTRODUCTION
As mentioned in the introductory chapters, prions are misfolded proteins capable of

transforming soluble monomeric counterparts into misfolded forms. These prion-like proteins are
pathogenic agents which spontaneously aggregate into toxic oligomeric and proto-fibrillar seeds
that serve as templates for the continued soluble-to-toxic conversions.142,143 Today, we know that
the prion protein shares its prion-like tendencies with several other proteins, including amyloid
proteins, such as Aβ, Tau, α-Syn.142,143 An essential characteristic of these seeds is their ability to
spread from the original locus to distant neuronal domains (Figure 8). 27,144
Amyloidosis is all diseases in which misfolding proteins, namely “amyloids,” change from
monomers' soluble form into more toxic oligomeric aggregates.87 These aggregates tend to build
up within the cells, interfering with cellular homeostasis and associated pathologies. The solubleto-toxic transformation of amyloid proteins is the hallmark of many NDs. An example is Aβ fibril
formation, hyperphosphorylated Tau in AD, α-Syn aggregation, Lewy bodies (LBs), and Lewy
neurites (LNs) in PD, which are known to be prions-like proteins.130,145 Similar relations are
observed with mutant huntingtin protein (mHTT) in Huntington's disease (HD), as well as in nonneurodegenerative disorders conditions (NNDs) such as systemic amyloidosis and diabetes. 146–148
This means that the self-seeding mechanism characteristic of the prion protein has been attributed
to other NDs. While some amyloids proteins are known to be prion-like, emerging data have
revealed that they are also able to seed the misfolding of prion-like proteins differing in sequence.
An interesting angle of these prion-like proteins is their ability to self-propagate and spread
throughout the neuronal network and recruit their soluble counterparts in adjacent neurons.74,149,150
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The transmission from a corrupted neuron can occur through several mechanisms, such as axonal
transport, internalization via endocytosis, nanotubes, vesicular transport, and even direct
infiltration of the plasma membrane (Figure 8). 151,152
Nevertheless, experimental evidence for amyloid cross-toxicity at the vertebrate level
remains indirect, lacks resolution, or introduces confounding variables. It is believed that these
seeds tend to propagate from the neurons that originated (releasing neuron) in other adjacent
neurons (recipient neuron) neurons in the brain (Figure 8). Nevertheless, recent findings suggest
a heterotoxic potential in these “seeds” whereby one neurodegeneration-associated protein can
interact with another unrelated prion-like protein, exert influence on its aggregation and lead to
cross-toxic outcomes and neurodegenerative co-morbidity. Therefore, it is interesting to
understand the mechanism that drives foreign amyloid into the soluble monomer-to-toxic oligomer
conversion of the constitutive amyloid and spur cross-seeding outcomes and cross-pathology.
Mounting evidence using post-mortem analysis have shown that >50% of AD patients
present with a significant amount of LBs and LNs; conversely, patients present with Aβ plaques
and neurofibrillary tangles (NFTs) in LBs diseases leading to PD with dementia (PDD) and LB
with dementia (LBD), respectively.27,95 In vitro studies reveal interactions between Aβ, α-Syn,
and Tau, and between mHTT and Tau phosphorylation impact Tau distribution.90,152,153 Other
studies have revealed aggregates of Aβ and Tau surrounding α-Syn. 27,47,154,155 In others, in vitro
and in vivo studies have shown a possible synergistic effect between these two pathological
proteins in Tg mice by promoting one another's aggregation.156–159 APOE status, which traditionally
signals risk and onset in AD, is also associated with PD.160–162 The gene encoding Tau, MAPT,
has been linked to frontotemporal dementia (FTD), progressive supranuclear palsy, and more
recently to PD, as it demonstrates a statistically significant convergence to co-morbidity among
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patients with neurodegenerative disorders.130,163–165 For example, ∼30% to 40% of patients with
PD present with dementia during the disease course, and ~30% of patients with AD develop
locomotor deficits.166,167 These data collectively point towards overlapping neurometabolic factors
that may drive heretofore seemingly unrelated disorders. Cross-seeding may be a possible
mechanism by which patients with neurodegenerative disorders present overlapping clinical
symptoms. 168–170
Tg animal models designed to address the role of neurometabolic overlaps suffer from
limitations.93,171,172 Many studies have demonstrated the cross-seeding and spreading of α-Syn in
Tg mice overexpressing Aβ plaques and Tau aggregation. 146,152,173,174 However, Tg studies lack the
level of isolation required to adequately pinpoint the role of individual neurometabolic factors in
triggering cross-toxicity and cross-pathology. Specifically, such models cannot prevent the
prevalence of additional neuronal factors that may be causals for cross-pathology (in addition to
the said). Finally, there is a poor lack of control concerning dose, the time frame of amyloid entry,
and chronic vs. acute models of amyloid metastasis in Tg animal studies. Previous studies have
shown the correlation of long-term amyloid protein deposits with cognitive, sensory, and memory
impairment in nontransgenic (NTG) mice.146,175,176 The advantage of using long-term study is that
they allow researchers to mimic human pathological conditions such as the problems occurring in
many neurodegenerative disorders characterized by a chronic and slowly progressive process.
127,177–181

This study aims to identify preclinical outcomes associated with the infiltration of amyloid
protein into a neuronal assembly where the said amyloid is not endogenously expressed. We use
an oligomeric form of amyloid peptides, i.e., Aβ (1-42) and Aβ (25-35) at a concentration of 100
μM. Both Aβ peptides are appropriate for better understanding the self-propagating, spreading
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behavior and the neuronal oxidative stress induced by oligomers of Aβ.21,182 Aβ (1-42) is found to
be the most abundant form of Aβ in senile plaques and the ability to aggregate into soluble Aβ
oligomers or insoluble fibrils, which are responsible for the Aβ plaques.154,169,183 On the other hand,
the Aβ (25-35) is a by-product of the (1-40) peptide and retains similar toxicity to the full-length
Aβ (1-42) and, additionally, is easily endocytosed.31,184–186 The comparison between these species
in a PD compromise brain area allows us to better understand the mechanism by which AD could
synergistically interact with one another using a common causal agent and a well-established
truncated variation of the same insult.88,89,95
The experimental design is directed towards limiting interference from other
neurometabolic factors present, as previously discussed, in Tg animal models. Using stereotaxic
surgery, we introduced the oligomers form of Aβ directly into the rodent midbrain (Tegmentum),
a locus that does not natively express the said amyloid. Subsequently, we measured behavioral
outcomes associated with the entry of this exogenous amyloid into vertebrate neurons and the
molecular and cellular transformation that occurred at 3 months, 6 months, 9 months, and 12
months, potentially corresponding with stages of amyloid protein fibrillization. We hypothesize
that non-native amyloid entry into heterotypic neurons will significantly corrupt the host neuronal
assembly and drive cross-toxic outcomes (Illustration 2). We test this hypothesis in a rodent
model by introducing Aβ peptide into a WT rat midbrain (Tegmentum), a locus that can model
amyloid entry into heterotypic neurons. This project was based on joining collaboration with
Mahesh Narayan, Ph.D. Edward Castañeda, Ph.D. Amy Wagler, Ph.D. and Soyoung Jeon, Ph.D.
Lois Mendez, Erick Guerrero, Ariel Schmid, Stephen Collins, Daniela Gonzales.
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Illustration 2. Schematic Representation of a Hybrid Model to Study
Amyloid Cross-Toxicity. This model combines a stereotaxic introduction of an amyloidogenic
protein into the rat locus and observes its molecular and organismal outcome associated with the
amyloid infusion. Figure reproduced from reference. 187
5.2

RESULTS

5.2.1

Aβ Size and Dynamic Light Scattering (DLS) Determination.
Figure 22 depicted the size of Aβs distributions used in this study, (Figure 22 A) show the

monomeric form of Aβ (1-42), (Figure 22 B) show the oligomeric form of the Aβ(1-42), and
(Figure 22 C) demonstrates the oligomeric form of the Aβ (25-35) fragment in solution after being
prepared were sized using dynamic light scattering. The method used for Aβ preparation and
analysis is presented in chapter 3, materials and methods (3.1.2 and 3.1.3).
5.2.2

Evaluation of Behavioral Motor Posterior to an Amyloid Infusion
We assessed behavioral tests that are sensitive to a diverse degree of nigrostriatal

dysfunction at 3, 6, 9- and 12-months post-infusion (m.p.i) (Figure 23 A-D). In order to evaluate
intact sensorimotor skills and dexterity, we conducted the Adhesive removal test (Figure 23 A).107
We observed that rats became more adept (i.e., faster) at sensing the adhesive stimulus (time-to
contact) and eliminating it (time-to removal) over time (3, 6, 9, and 12) across all groups (Figure
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23 A). However, a PD rat would take longer to perform these tasks. We do not observe any
significant differences for either of these two metrics between the infusion groups and the vehicle
controls. We also evaluated locomotor asymmetry using the Cylinder test (given the unilateral
infusion of the amyloid insult) (Figure 23 B).111 We found a linear decrease in the number of
spontaneous paw touches (supported rears) against the plexiglass wall at 9 and 12 m.p.i (Figure
23 B). However, a PD rat would take longer, the reduction presented in this graph, may be due to
lack of motivation. When these timepoints were compared to performance at 3 m.p.i, there was no
significant differences in supported rears between the infusion and control groups (Figure 23 B).
The skilled limb placement was additionally evaluated utilizing the Ladder-walking test.112 The
number of slips and month post-infusion (m.p.i), displaying an increase across time; however, no
significant differences were observed between groups (Figure 23 C). Lastly, we evaluated motor
neuromuscular impairment via the Wire-hang test (Figure 23 D).113 The data indicated no
significant difference was found between treated groups and vehicle, a PD rat would take longer
to release from the wire as they muscle would be tense. The method used for behavioral analysis
is presented in chapter 3, materials and methods (3.2.4), and (Figure 10).
B.

A.

Intensity

C.

Figure 22. Size Distributions of Prepared Aβ (25-25), Aβ (1-42). Dynamic
Light Scattering (DLS) data of the larger size of oligomer preparation. (A) Monomeric form of
Aβ(1-42) (B) Oligomeric form of the Aβ(1-42) (C) Oligomeric form of the Aβ (25-35)fragment.
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Figure 23. Motor Deficits in Aβ WT Rat. (A-D) Behavioral
assessment of WT rat 3,6,9,12 m.p.i. (n= 11-30) rats per group for each
time point are shown after a single unilateral infusion of Aβ (25-35)
and Aβ (1-42) into the midbrain of WT-Lewis rats. (A) Results of
animals on the Adhesive Removal test with two parameters, time to
contact the stimuli (left) and time to remove the stimuli(right). (B) Paw
touches performances on the cylinder. (C) Result of animals’
performance on the Ladder test. (D) Rat’s latency to fall from the wire.
Data are mean values S.E.M compared to the control group and across
the months.
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5.2.3

Quantification of TH+ Neuron Posterior to the Amyloid Infusion
We quantified the dopaminergic neurons within the SNpc via immunohistochemical

analysis (Figure 24); the method used for this assay and analysis is presented in chapter 3,
materials and methods (3.2.5). Figure 24 A shows the infusion site in the midbrain (Tegmentum)
area as verified with the inserted needle placement with the Nissl staining. This staining method
demonstrates the injection's effectiveness into the midbrain (tegmentum), a locus that does not
endogenously express Aβ. It also facilitates postmortem neurobiochemical assays by identifying
a region of interest defining amyloids differing in sequence (for example, the substantia nigra pars
compacta (SNpc)) (Figure 24 B-C). A Kruskal/Wallis one-way ANOVA revealed no significant
difference in the number of TH+ neurons amongst the treated group with the vehicle group (Figure
24 H). The stereological analysis revealed that administration of the Aβ did not induce a loss of
TH+ in the rat at 3,6,9 and 12 m.p.i.
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Figure 24. Aβ Injection in the Midbrain and the Effect in the DA Neuron. (A)
Representative image of the needle placement with the Nissl staining. (B-C) Indicate the site of
stereotactic inoculation into the rat brain and the TH+ dopaminergic neuron in the SNpc and VTA.
(D-G) Double Immunofluorescence (IF) staining was conducted for NeuN (red) and TH neurons
(green). White scale bar: 100 µM. (H) Quantitative analysis of TH+ neurons in the SNpc at different
time points after Aβ or DMSO injection. n= 5-14 rats per group for each time points. Due to interassay variability, data are presented as a ratio of the number of TH+ neurons in the ipsilateral Abtreated SNpc/VTA to the contralateral intact hemisphere (mean + SEM). Images were obtained in a
confocal microscope 20X objective; scale bar measures 100 μM.
5.2.4

Colocalization of α-Synuclein and Thioflavin S Within the SNpc
In this study, we stained rodent brain tissues to assess molecular and cellular analysis

associated with the introduction of oligomeric Aβs in the midbrain (Tegmentum). Dual staining
resulted in the colocalization of phosphorylated α-Synuclein (Pα-Syn) and a subset of Aβ deposits
(Figure 25 & 26). Aβ plaques take on fibrillar and β-pleated sheet conformations; they can be
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visualized with the amyloid-binding dye thioflavin S (ThS). Phosphorylated α-Syn can be
visualized with a fluorescent probe (Anti-Alpha-synuclein (Phospho at Serine 129) (Figure
25).120,188,189 Measurement of amyloid aggregates and their colocalization with Pα-Syn, was done
by ImageJ software, we obtained the signal intensities for the colocalization of both probes.
(Figure 25 A-F). The cell's minimum and maximum pixel values were confirmed in the heat map
(Figure 25 D-E), depicting the relative magnitude of reporter signals. As reported in the figure,
the intensity of the red and green determine the colocalization by the yellow areas.
Quantitatively, colocalization was measured by applying specific algorithms that calculate
the degree of colocalization coefficients. One of the algorithms used for measuring the degree of
colocalization was the Pearson's Correlation Coefficient (PCC). PCC calculates the pixel-by-pixel
covariance between the intensities distributed in the two images.117 For example, between ThS
(green) and Pα-Syn (red) in this study.153,154 In (Figure 26 A), we observed a strong correlation
between ThS and Pα-Syn in the Aβ (25-35) group at 6 m.p.i in the ipsilateral side compared to the
ipsilateral side of the vehicle. Still, no significant correlation was found for the rest time points nor
the Aβ (1-42) group as compared to the vehicle control. A similar trend was observed when
colocalization was calculated with the algorithm based on Mander's overlap coefficient (MOC)
(Figure 26 B). Mander indicates the overlap of the signals (co-occurrence).117,188,190 It estimates the
contribution of a single color in the colocalized area to the total colocalized fluorescence within
the image, giving two values (M1 and M2) (Figure 26 B-C). Graph M1 of (Figure 26 B) defined
the contribution of the fraction of the red channel (Pα-Syn) to the colocalized area in compartments
containing the green channel (ThS). By contrast, the M2 graph (Figure 26 C) describes the
contribution of the green channel in compartments containing the red reporter channel. The range
of both coefficients goes from 0 to +1 for the MOC and −1 to +1 for the PCC. This means that a
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value of +1 is a perfect correlation, −1 is known to be a perfect but negative correlation, and 0,
which denotes the absence of a relationship (Figure 26). 119,121,122
Our data showed that the M1 graph (Pα-Syn/ ThS) was significantly higher for the Aβ (2535) group in the ipsilateral side at 6 m.p.i. When compared to the vehicle group, indicating that
Pα-Syn was colocalized within the ThS-amyloid deposits. The M2 (ThS /Pα-Syn) value
demonstrated significantly stronger intensities at 6, 9, 12 m.p.i on the Aβ (1-42) and Aβ (25-35)
groups relative to the vehicle group (p <0.001). The results of ThS positive amyloid deposits and
Pα-Syn staining suggest that the colocalization between these two pathological proteins increased
over time after Aβ (1-42) and Aβ (25-35) infusion.
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Figure 25. Qualitative Analysis of Aβ Plaques Correlate with Pα-Syn.
(A-C, F) Representative image using PS129 α-Synuclein antibody and Thioflavin S
staining on tissue sections from WT rat midbrain. Scale bars: 50 µM. (D-E) Heat maps of
the red channel (Alexa 568) and green channel (ThS dye), respectively, visualize
localized regions of signal intensities. Images were obtained in a confocal microscope
40X objective; scale bar measures 100 μM
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Figure 26. Quantitative Analysis of Aβ Plaques Correlate with
Pα-Syn. (A-C) Bar graphs show a positive association between Aβ plaque and PαSyn, using Pearson's correlation coefficient (PCC) and the overlap coefficient
according to Manders' (MOC). EZ Colocalization, an ImageJ plugin, was used for
visualizing and measuring colocalization. An average of the examined samples' region
of interest (ROI), n= 5-14 rats per group for each time point, is shown. A KruskalWallis test was used for the analysis in (A, B and C) graph (* p <0.05; ** p <0.01;
*** p < 0.001). Data are presented as mean ± SD. Black bars represent ipsilaterally,
and white bars. represent contralaterally sides.

5.2.5

Aβ Infusion Within the Tegmentum Area Induce α-Syn Pathology
The toxic forms of α-Syn, such as soluble oligomers and protofibrils, contribute to DA

neuron degeneration. Previous studies have reported that Pα-Syn may be critical in PD
pathogenesis in nontransgenic mice and causes motor dysfunction.191,192 Immunostaining for PαSyn (red channel) was visibly observed in the SNpc (green channel), corroborated by the TH+
staining, indicating that Aβ seed can increase the formation of α-Syn aggregates therein.152,193 In
this study, α-Syn pathology in the midbrain region was positively associated with Aβ introduction
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(Figure 27 ). Representative images (Figure 27 ) reveal that after the infusion of the oligomeric
form of Aβ, the expression of Pα-Syn (red) increased over time when compared to the vehicle
group.
Quantitatively, data obtained using PCC and MOC coefficient (Figure 28) showed
significant levels of Pα-Syn inclusion proteins within the SNpc (Figure 28 A-C). The PCC graph
showed the appearance of Pα-Syn in the ipsilateral side of the Aβ (25-35) groups at 6 m.p.i (Figure
28 A). A significant increase was observed on both Aβ groups in the ipsilateral and contralateral
sides at 9 and 12 m.p.i. This result indicates that the intraneuronal Pα-Syn inclusion within the
SNpc increased overtime after the exogenous oligomeric proteins were taken up by DA neurons,
a process that occurs with time. Previous studies have demonstrated that Aβ peptides in their toxic
form (oligomers) in the brain can promote the formation of intracellular Tau and α-Syn amyloid
aggregates.88
We calculated the pixel ratio of the red channel (Pα-Syn) and green channel (TH) in the
colocalized area using MOC (Figure 28 B-C). Increased signal intensity was observed at 9 m.p.i
in the ipsilateral side for the Aβ (25-35) compared with its contralateral side (Figure 28 B).
Interestingly, the Aβ (1-42) group at 9 and 12 m.p.i showed a decrease in the intensity in the
contralateral side, but not in the ipsilateral when both groups were compared (Figure 28 B).
Finally, in the M2 graph, it is evident that pixel overlapping is similar in both hemispheres in the
Aβ (25-35) and Aβ (1-42) groups (Figure 28 C). Significant overlapping was observed at 6 m.p.i
in the ipsilateral side for the Aβ (25-35) compared with the contralateral side. After 9 m.p.i, the
appearance of Pα-Syn (red channel) in the contralateral side of the Aβ (25-35) group was higher
than in the control group.
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Similarly, an increased signal intensity at 9 m.p.i in the ipsilateral side for the Aβ (1-42) was higher
than the intensity found in the ipsilateral side of the vehicle control. A similar trend was observed
after 12 m.p.i when the expression of the Pα-Syn was increased in the ipsilateral side of the Aβ
(25-35) group when compared to the ipsilateral expression on the control group. A significant
increase was also observed in the contralateral side of the Aβ (1-42) group compared with the
control's contralateral side. In conclusion, data indicated an increased level of Pα-Syn within the
SNpc after Aβ infusion in both Aβ groups compared to the control animals. The intensity observed
in both hemispheres at different time point indicates a transmission of Pα-Syn occurring through
network projections into DA neurons.
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Figure 27. Representative Image of Aβ Plaques in the SNpc.
(A-D) Image using Ser129 Pα-Syn antibody red channel (Alexa 568) and
Tyrosine Hydroxylase staining in WT- rat. Scale bars: 100 µM green channel
(A-488), DAPI dye (blue) for nuclear staining.

A
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Figure 28. Quantitative Colocalization of Pα-Syn in the SNpc.
(A-C) Bar graphs show a positive association between Pa-Syn DA neurons in the
SNpc, using (PCC) and the overlap according to (MOC). An average of the
coefficients of examined samples n= 5-14 rats per group for each time point is
shown. One-way analysis of variance (ANOVA) was used for the analysis (*p
<0.05; **p <0.01; ***p <0.001). Data are presented as mean ± SD. Black bars
represent ipsilaterally, and white bars represent contralaterally.
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5.2.6

Aβ Infusion Provoke Impairment of the Ubiquitin-Proteasome System
Impairment of the UPS has played a central role in PD etiology.131,194,195 Protein aggregates

that onset neurodegenerative disorders may interact with the cellular proteasome and inhibit its
activity.146,174 Since UPS is the principal route for degradation, its dysfunction contributes to protein
clearance impairment and neuronal death.195–197 We investigated nigral UPS status under the Aβ
insult (Figure 29). The representative image demonstrates the colocalization of Pα-Syn and
ubiquitin at different time points. Triple IF staining was conducted for ubiquitin (red), pα-Syn
(green), DAPI (blue) in the midbrain area of an Aβ- WT rat model. The data indicate a possible
role played by Aβ aggregation in altering protein clearance that drives the increase in Pα-Syn. It
is notable that Pα-Syn protein is found in LB aggregates and is highly used as a marker for
pathological α-Syn.146,180

Figure 29. Aβ/Pα-Syn Co-Pathology Leads to UPS Impairment. (A-B)
Confocal microscopy of triple immunofluorescence of phosphorylated α-Synuclein (Pα-Syn;
green) and Ubiquitin (red) of all treatment groups within the Tegmentum area throughout the
study. (A) The Ipsilateral side of the infusion and (B) The contralateral side of the injection—
scale bar: 50µM.

86

5.3

DISCUSSION
The abnormal accumulation of toxic proteins in neurons, coupled with the loss of cellular

homeostasis, is a common denominator across several neurodegenerative disorders.165,198 These
aggregated proteins become large heterogeneous amyloid inclusions commonly found in NDs. The
mechanism by which amyloid proteins are found in the central nervous system (CNS) has been
the focus of many NDs researchers and remains unclear. Published studies demonstrate a strong
relation between Aβ plaques, Tau tangles, Pα-Syn, and their interactions, provoking
neurodegeneration.88,89,95 Co-pathology in neurodegeneration is evident at the molecular level and
in clinical presentations. It has been observed that patients who were suffering from one
neurodegenerative

disorder

also

present

symptoms

of

other

neurodegenerative

diseases.147,148,153,171,199 Therefore, there is a need to define the mechanism(s) by which amyloids
differ in sequence promote mutual aggregation, leading to the onset of clinical co-morbidity.
This study develops a model to address the molecular origins of co-morbidity seen in
neurodegenerative pathologies. Our model examined the mechanism by which amyloidogenic
proteins could interact with endogenous proteins to induce crossover neurodegeneration.200,201
Amyloidogenic proteins can self-seeding and transmission through the neuronal network (Figure
8). In this study, our objective is to understand the consequences of an amyloid protein entry into
neurons where they are not endogenously expressed. As aforementioned, this study examined
behavioral and cellular outcomes related to amyloidogenic vectors in heterotypic neurons. We
injected oligomeric Aβ into the tegmentum area of WT rats. Initially, we examined behavioral
effects associated with the entry of Aβ. Following injection, rats underwent a series of
sensorimotor behavioral tests over a time course of 3, 6, 9, 12 months post-infusion (m.p.i.).
Despite peptide infusion within the midbrain area, no motor impairments were observed in all
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behavioral tests. Previous studies suggest that function impairments on motor behavioral are
associated with a higher level of unilateral nigrostriatal degeneration ~90% -95% of the total loss.
Our study was not possible to observe notable changes in motor outcomes simply because no DA
lesion was found.113,177,195,202 Previous studies had reported a similar trend when nontransgenic mice
were unilaterally injected with α-Syn directly into the hippocampus and cortical area. 203–206
Mounting evidence has demonstrated the link between α-Syn and Tau, which can
polymerize into amyloid fibrils and internalize intracellularly.88,89,95 It has been observed that
exogenous oligomeric proteins can be internalized by neurons and trigger endogenous proteins'
misfolding to neuronal dysfunction and death.79,207 However, the mechanisms by which neurons
near the infusion site might be affected by the amyloid deposits need further investigation. It is
known that Aβ (25-35) peptide, i.e., GSNKGAIIGLM, represents the shortest fragment of Aβ,
processed in vivo by brain proteases. It has been thought that Aβ (25-35) is more soluble than the
Aβ (1-42) and retains the toxicity of its full-length. Aβ (25-35) is more prone to be uptake by
endocytosis, making it easier to study the potential corruption of other proteins and induced loss
of dopaminergic neurons resulting in motor impairment.208 Previous papers have reported that Aβ
(25-35) in its mono/oligomeric forms can cross the cellular plasmatic membranes inducing
intracellular mechanisms of toxicity. It is thought that they can enter the cells and cause
mitochondrial damage, which triggers apoptotic signals. Aβ (25-35) is mainly used in animal
studies and has been demonstrated to trigger molecular changes similar to what has been seen in
human AD.15,21,179,182
On the other hand, PD is characterized by neuronal loss of neurons within the SNpc and
the consequent reduction in striatal DA levels.39,110,209 DA neurons play an important role in the
brain, such as controlling voluntary movement, behavioral processes, and synaptic plasticity
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modulators.113,177,210 In this study, we performed immunofluorescence (IF) analyses to evaluate the
effect of Aβ oligomers' progression on the expression of TH+ in the SNpc. Histologic analyses
revealed that TH+ is not significantly affected by Aβ. This result is consistent with our behavioral
findings, where no motor abnormalities were observed, even after 12 m.p.i in all
groups.174,175,193,205,207
The presence of aggregated α-Syn associated with other proteins found in the cytoplasmic
inclusions (LBs and LNs) in the SNpc and other regions of the brain is another hallmark of
PD.47,161,211–215 The protein α-Syn is the most abundant constituent in LBs and LNs, specifically αSyn, phosphorylated at the serine 129 (Ser129) accounting for 90% of all α-Syn in LBs inclusions
in contrast with only 4% in a healthy brain.216,217 Previous studies have reported that the
administration of prefibrillar form of α-Syn into rodents' brains is toxic and can cause degeneration
of dopaminergic neurons.153,175,195,201 In this study, we observed the presence of Pα-Syn within the
SNpc after Aβ infusion. Therefore, it is plausible that Aβ into the SNpc resulted in the corruption
of α-Syn status into its phosphorylated form. This phenomenon is proven in model cell line
studies.216 Pα-Syn binding inhibits TH+ neuron activity, which potentially leads to α-Syn
pathology to DA neuron loss and possible behavioral alterations.51,195,210,218
To address the possibility of cross-toxicity between PD and AD, we studied the outcomes
caused by the introduction of amyloidogenic proteins into heterotypic neurons. The presence of
these proteins may cause a synergistic influence of each other by promoting aggregation and
ultimately leading to neurodegeneration. Notably, the stereotaxic method of infusing a single type
of amyloid peptide in its oligomeric form into a heterotypic locus reduces the chance of
confounding neurometabolic factors playing a role in cross-toxicity. ThS staining allowed us to
detect and quantify amyloid-like fibrils and insoluble aggregates. Furthermore, tissues that were
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double immunostained with the ThS staining confirmed the ability of the foreign amyloid, viz. Aβ,
to convert endogenous soluble monomeric α-Syn into phosphorylated aggregates.
The colocalization between Aβ deposits and Pα-Syn was obtained by measuring pixel
correlation. The positive correlation and co-occurrence observed at 6 m.p.i on the ipsilateral side
of the Aβ (25-35) group demonstrated that Pα-Syn was present after the infusion of amyloid
oligomers. The overlap between the two proteins supports the idea that Aβ promotes Pα-Syn
aggregation. However, the mechanism by which this occurs needs further clarification. This
finding is consistent with previous studies that showed that Tau protein facilitates the spread and
seed of α-Syn in the form of LBs and LNs. Other studies have demonstrated the synergistic effect
of Aβ and Tau proteins, or the convergence of all three (Aβ, Tau & α-Syn), but the interaction
between Aβ and α-Syn has been challenging to demonstrate 75,146,154,219
As previously mentioned, Ser129 α-Syn phosphorylation (Pα-Syn) is pathogenic and the
primary component of LBs and LNs. It facilitates neurotransmitter leakage and leads to DA neuron
loss. We assessed the impact of Pα-Syn on SNpc after the Aβ infusion in this area. Our result
suggests that Aβ facilitates the aggregation of endogenous α-Syn within the dopaminergic
neurons. Furthermore, our results showed that Pα-Syn positively correlates in the Aβ group
relative to the vehicle. Our work, taken in conjunction with other studies, suggests that Pα-Syn
may significantly inhibit TH+ activity.153,174,195 Based on the gathered data, we conclude that
exogenous misfolded Aβ contributed to the endogenous accumulation of α-Syn and the formation
of the significant LB component, Pα-Syn. Previous studies have reported that the progressive
accumulation or an exogenous inoculation of α-Syn within the SNpc may contribute to nigral
degeneration in response to aggregation.51,152,175,193,195,220 However, the appearance of α-Syn and the
dopaminergic neuron dysfunction remains elusive, and further study is needed to understand the
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mechanism by which Aβ triggers the aggregation of Pα-Syn in thus the induction of DA neuron
loss.
A common statement in many scientific works is that the accumulation of amyloidogenic
proteins characterizes the majority of neurodegenerative diseases. For the brain to eliminate
misfolded proteins, mammalian cells need to tag them for degradation.219,221–224Their accumulation
leads to abnormal protein homeostasis and neuronal death. Therefore, to maintain the health of
cells, the degradation process needs to be functioning adequately. The ubiquitin-proteasome
system (UPS) protein is impaired in AD and PD, causing severe cellular protein degradation
pathway dysfunction. In this study, we hypothesized that Aβ impaired UPS and thus results in the
accumulation of Pα-Syn since Aβ induced UPS failure and attenuated the degradation of
misfolded proteins. Our result demonstrated that the expression of Pα-Syn exceeded the
immunoreactivity for ubiquitin. Prior studies showed that misfolded proteins, such as Pα-Syn,
impair the UPS functioning and enhance neurotoxicity, aggregation, and cellular death. We
concluded that Aβ is interfering with the UPS by enhancing the accumulation of Pα-Syn, which
impaired the UPS. 78,197,221,225,226
5.4

CONCLUSION
The presence of amylogenic proteins with prion-like characteristics has been reported in

several neurodegenerative diseases. After being exposed to specific behavioral studies, previous
studies have reported motor dysfunction in the Tg-amyloidogenic animal model associated with
loss of dopaminergic neurons and deficits in working memory. Nevertheless, a study using WT
animals showed no gross motor abnormalities after exogenous aggregated α-Syn infusion. The
rats do not exhibited reduction in striatal dopaminergic innervations after 180 days of infusion.
Therefore, it was insufficient to elicit motor deficits in the behavioral tasks. However, when post-
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mortem tissues were analyzed, it was possible to observe cytoplasmic inclusions of LBs and LNs
in the cells. These studies suggest that amyloidogenic proteins such as α-Syn, Tau, and Aβ, could
synergistically interact and induce aggregated inclusions, plaques, and tangles leading to a crossseeding effect in several areas of the brain and a significant loss of neuron function leading to
behavioral deficit. However, the mechanism underlying AD or PD in WT animals'’ exogenous
amyloid protein infusion may differ. The differences observed between the Tg and WT rodents
underscore important factors when developing an NDs experimental model for future studies.
Our study revealed that a single unilateral infusion of the oligomeric form of Aβ into WT
rats' tegmentum is sufficient to lead to PD's pathological features at the molecular level by the
seed-initiated mechanism. However, we did not observe significant motor impartment in any of
the behavioral assessments performed after unilaterally infusing peptides in the SNpc of WT rats.
Previous studies have reported that high levels of unilateral nigrostriatal denervation (~80-90%)
are needed to influence forelimbs asymmetry significantly. Ongoing studies are required to
determine whether increasing the Aβ dose by providing a dose response curve, infuse directly to
the SNpc, or preform a chronic infusion via an osmotic pump, will increase the magnitude of
degeneration and thus allow PD behavioral deficit to emerge.
Furthermore, Aβ infusion led to Pα-Syn aggregation, a cross-species interaction,
potentiating fibril formation and toxicity. Notably, these findings help reconcile the incidence of
clinical convergence of co-morbidity seen in a significant fraction of patients with
neurodegenerative disorders. Furthermore, by implicating crossover neurometabolic factors in
amyloid-driven diseases, targets for intervention can be identified. Finally, the methodological
inroad permits researchers to pursue studies that can reveal other crossover factors in the
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neurodegenerative landscape and is valuable for testing combined therapies that target more than
one disease. Finally, all materials and methods used in this work are presented in chapter 3 (3.2).
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Chapter 6
Neuroprotective Effect of Citric Acid Carbon Quantum dots Against Environmental
Toxicant Driven Neurometabolic Deficits
6.1

INTRODUCTION
Parkinson’s disease (PD) is a chronic progressive disease of the ND family, affecting 1%

of the population over 55. The genetic forms of the disease represent less than 10% of the current
cases, with 90% belonging to the sporadic form of the disease.39 PD comprises motor symptoms
including resting tremor, rigidity, and bradykinesia due to the cell death of dopaminergic neurons
responsible for the onset of Parkinsonian syndrome. Mounting evidence suggests that
environmental toxins trigger neurodegeneration of nigrostriatal dopaminergic neurons. The
prolonged use of pesticides, including Rotenone, MPTP, and Paraquat, has been linked to
parkinsonism in humans. Multiples epidemiological studies highlight an association between
increased PD risk and environmental factors in rural life. Another key pathological characteristic
of PD is the presence of cytoplasmic inclusions LB and LN within the dopaminergic neurons (DA)
in the Substantia Nigra parc compact (SNpc).39,110,215 These inclusions are made of the protein αSyn, which tends to self-aggregate and leads to neurodegeneration in the presence of oxidative
stress and other factors. It has been reported that specific environmental toxicants can modify the
structure of α-Syn and interfere with the ubiquitin-proteasomal pathway (UPS), thus promoting αSyn aggregation, which can impair the degradation process of abnormal protein.227
Paraquat (methyl viologen) is a non-selective contact herbicide commonly used to control
weeds and grasses. It is a mitochondrial neurotoxicant that induces Parkinson-like features in nonprimate humans, rodents, and humans.227,228 The mechanism by which Paraquat leads to
neurodegenerative disease may be through its redox cycle. Paraquat is reduced by various
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mechanisms,

including

N-methyl-d-aspartate

(NADPH)-cytochrome

P-450

reductase,

mitochondrial complex I, to form free radical (PQ•+ ). Afterward, this free radical is re-oxidized in
the presence of oxygen to generate superoxide radical (O•- ), leading to the generation of reactive
oxygen species (ROS), which trigger cellular dysfunction.227,228
The mechanism by which Paraquat induces neurotoxicity to develop PD suggests that this
herbicide can penetrate the central nervous system (CNS) and produce injury to the DA neurons
in (SNpc) and, consequently, provoke the characteristic symptoms of PD. Therefore, Paraquat is a
good candidate for generating an oxidative stress model in the laboratory, particularly when
combined with the SH-SY5Y cell line that mimics the human DA neurons used as a cellular PD
model and the nematode, Caenorhabditis elegans (C. elegans). This in vivo model has been used
in toxicological studies because they are susceptible to the aforementioned environmental
neurotoxins. Moreover, the advantage of using C. elegans is that they possess a short and prolific
life cycle, small and transparent body size, ease of maintenance, invariant and fully described
developmental program, and a well-characterized genome. This study used the Tg BZ555 (Pdat1:GFP) expressed explicitly in dopaminergic neurons. BZ555 possesses a total of eight DA
neurons, including two pairs of cephalic (CEP) and one pair of anterior deirid (ADE) in the head
position, and also possess one pair of posterior deirid (PDE) in the posterior lateral region. The
eight neurons helped to quantitatively analyze the percent of neurodegeneration and protection by
using fluorescent protein labeling GFP. These features have led to using these C. elegans strains
in toxicology studies and toxicity screening approaches. However, C. elegans has typically been
used to screen toxicity based on the dose-response of surviving worms but added that this model
could evaluate the DA neuron sensitivity to neurotoxicants.229
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Since Paraquat induces toxicity by producing oxidative stress, an antioxidant agent is
necessary to inhibit free radical generation and suppress oxidative damage. The use of
nanotechnology has made a significant contribution to the scientific and industrial community.
Carbon quantum dots (CQDs) are carbon-based nanoparticles with a strong photoluminescence
quantum yield (PL QY).123 They have attracted much more attention due to their high chemical
stability, biocompatibility, and low toxicity. They are considered promising materials for many
biological applications.66 This study used Citric Acid-based Carbon Quantum Dots (Cit. CQDs)
made in our laboratory using green chemistry and eco-friendly nanoparticle methods and averts
the use of toxic materials.66,230In this study, we examined the protective effect of Cit. CQDs on DA
neurodegeneration using in vitro and in vivo models, viz. the SH-SY5Y cell line and the C. elegans
nematode. These two models offer an attractive platform for PD research. This project was based
on joining collaboration with Mahesh Narayan, Erick Guerrero, and Jyoti Ahlawat.
6.2

RESULTS

6.2.1

Characterization of Citric Acid (Cit.) CQDs
Cit CQDs' morphology, size, absorbance/emission, and surface chemistry were analyzed

using a series of analytical instrumentation (Figure 30). Transmission electron microscopy (TEM)
was used to reveal the morphology of CQDs, which was observed to be spherical (Figure 30 A).
The histogram within Figure 30 A indicates the diameter distribution of Cit CQDs in between 120 nm in size. Figure 30 B display the UV-VIS absorption spectra of the as-synthesized CQDs,
where the absorption peak was observed between 300 and 375 nm in an aqueous solution. This
corresponds to the n to pi star transition of the functional groups present on the CQDs surface. The
Photoluminescence spectra in (Figure 30 C) show the excitation-dependent emission of the CQD
from 300 nm to 400 nm. The surface chemistry and the various functional groups of Cit CQDs
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were determined using the FT-IR spectra (Figure 30 D-Red). The Cit CQDs was in good
agreement with that reported in the literature (Figure 30 D-Black).66
To determine Cit CQDs antioxidant activity, we tested its free radical scavenging capacity
using the standard DPPH assay. In this experiment, we observed the diminution in the UV
absorbance maximum of the DPPH radical at 517 nm (Figure 31). Cit CQDs at concentrations of
20 to 100 µg/mL were able to quench the free DPPH radicals with a concentration dependent on
the absorbance, suggesting that Cit CQDs possess good antioxidant activity as it was capable of
scavenging free radicals and reducing the reactive oxygen species stress.
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Figure 30. Physico-Chemical Characterization Data of Cit CQDs. (A)
Shows the TEM image of Cit. CQDs. (B) Represents the absorbance spectrum of assynthesized CQDs, with the inset showing fluorescent images of the CQDs when excited
using the UV lamp. (C) Shows the excitation-dependent emission spectra of the CQDs,
and (D) Displays the functional group of CQDs as recorded using the FT-IR.

Absorbance (a.u.)

DPPH alone
+ 20 µg/mL
+ 40 µg/mL
+ 60 µg/mL
+ 80 µg/mL
+ 100 µg/mL

450

500

550

600

650

Wavelength (nm)

Figure 31. Antioxidant Capability of Cit CQDs. The figure shows the free
radical scavenging capability of Cit CQDs using the DPPH assay.
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6.2.2

Cit CQDs Attenuates of Paraquat-Induced Cell Death
As mentioned in the introduction, CQDs are suitable fluorescent probes used for biological

applications due to they possess high fluorescence quantum yield, non-toxic, and biocompatible
characteristics We tested these CQDs-as-synthesized in a human neuroblastoma cell line (SHSY5Y). First, CQDs were incubated with the cell line for 24 hours (Figure 32 A) to select optimal
concentrations of Cit CQDs for downstream experiments cells SH-SY5Y were exposed to a series
of engagements from 10-500 µg/mL. Figure 32 A shows the percentage of death Cit CQDs can
induce (cytotoxicity) in a dose-dependent manner. There was no difference between untreated or
vehicle and the Cit CQDs to cell up to 250 µg/mL concertation. This result suggests that Cit CQDs
have a low cytotoxicity effect in the SH-SY5Y cells. Seemingly, we also measured the potential
toxicity to cells upon Paraquat insult. The results reveal a smooth, dose-dependent increase in
cytotoxicity; more than 50% of cell death was observed at 2 mM of Paraquat (Figure 32 B). No
difference was observed between untreated or vehicle control and Paraquat treatment on cells up
to a concentration of 500 μM.
To assess the protective effect of Cit CQDs as a prophylactic and antioxidant agent against
the Paraquat at a concentration of 500µM, SH-SY5Y cells were pretreated with (50-500 μg/mL)
for 12 hours prior to the treatment of 500µM of Paraquat. This result indicates Cit CQDs possess
protective effects at a concentration of up to 500 μg/mL (p <0.05) and could protect the cells
against the Paraquat toxicity. Figure 32 D-I demonstrates a representative image of the protect
effect of Cit CDQs against the Paraquat insult.
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Figure 32. Cit CQDs Protected SH-SY5Y Cells from Paraquat-Induced Death. Paraquat
induces cytotoxicity on SH-SY5Y cells in a dose-depended manner. Cells were exposed to a
concentration gradient of Cit CQDs and Paraquat and incubated for 24 hours. Differential nuclear
staining assay and a bioimager were used to evaluate the cytotoxicity percentages(A-C; y-axis).
When experimental treatments were compared with the Paraquat, the p values were of <0.05.
Each experimental point represents the average of four trials and error bars corresponds to their
values ± SD. A representative live-cell images, merging the Hoechst and propidium iodide
(PI)channels, used to gather the cytotoxicity activity, depicted in (D-I). The nuclei in blue signal
are considered to be living cells, whereas nuclei exhibiting red color are considered dead cells.
6.2.3

Cit CQDs Alleviated Paraquat-Induced ROS Production

Reactive Oxygen Species (ROS) lead oxidative stress to cells and cause abnormal
intracellular metabolic reactions. Therefore, to protect the cells against neurotoxicant-induced
oxidative stress, we use antioxidant compounds that help to mitigate Paraquat ROS production. To
determine whether the pretreatment of Cit CQDs increase the generation of ROS by Paraquat, we
measured the intracellular ROS level by using the fluorescent probe carboxy-H2 DCFDA. Cells
were pre-treated with Cit CQDs at different concentrations and incubated for 12 hours. Then cells
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were treated with 500µM Paraquat for another 24 hours. In the posterior incubation period, cells
were stained with the fluorescent probe (carboxy-H2 DCFDA) at 10µM and incubated for an
additional 30 minutes under optimal conditions (see details in "Materials and methods" chapter 3).
Figure 33 demonstrates the green signal obtained with the probe as an indication of ROS level
triggered by the insult. The pretreatment with Cit CQDs resulted in a significant decrease in
Paraquat-induced ROS production. Finally, the data (Figure 33 ) suggest that the Cit CQDs can
reduce oxidative stress in human neuroblastoma cells.
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Figure 33. Neuroprotective Effect of Cit CQDs Against the Paraquat-Induced
Reactive Oxygen Species (ROS) in the SH-SY5Y Cells. Paraquat can induced ROS in a dosedependent manner. The relative fluorescence intensity was analyzed by fluorescence microplate
reader using the carboxy-H2 DCFDA probe. The statistically significant differences (p ≤ 0.0001)
are marked (*), with Paraquat-treated group are marked (**).

6.2.4

Impact of Cit CQDs and Paraquat on the Survival of C. elegans
We tested the protective effect of Cit CQDs on the Paraquat-induced toxicity of C. elegans.

A survival rate assay was performed with age-synchronized L1 transgenic BZ555 (Figure 34 AC) and WT N2 (Figure 34 D-F) worms. Worms were exposed to different Paraquat and Cit CQDs
concentrations for 72 hours (see details in "Materials and methods" chapter 3). Paraquat (1mM to
4 mM) increased the mortality rate in a time and dose-dependent matter up to 80% when compared
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to the untreated control or the vehicle (K-Medium) (Figure 34 A & D). Worms were also
pretreated with different concentrations of Cit CQDs (Figure 34 B-E). The graph shows that CQDs
improved the survival rate of the worm in both strains in a dose-dependent matter.
Furthermore, worms were pre-treated with the Cit CQDs for 24 hours and afterward
exposed to Paraquat for 72 hours. The CQDs protected the worms of the Paraquat-induced toxicity
(Figure 34 C-F). Table 3 shows the percentage of survival of worms pre-treated with CQDs. We
observed that BZ555 nematodes are more resistant to the Paraquat insult than the WT-N2 worms.
Data presented in this table are the survival functions between experiment and untreated control
groups at 72 hours of incubation. Based on the result presented here, we evaluated the effect of Cit
CQDs and Paraquat on dopaminergic (DA) neurons viability using only the Tg mutant worms
expressing GFP in the DA neurons (Figure 35).
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Table 3. Reporting Percentage of Survival
Treatment

Time

Percent

Percent

(hours)

mortality

Survival

p-value

BZ555 Strain
Untreated

4.44

95.56

K-medium

2.22

97.778

0.5535

Paraquat 2mM
Cit 0.25 mg + PQ 2mM

37.21

62.79

0.0001

13.33

86.67

0.1390

20

80

0.0254

24.44

75.56

0.0079

20

80

0.0243

Untreated

0

100

K-medium

4.44

95.56

0.1550

Paraquat 2mM

55.81

44.19

<0.0001

13.33

86.67

0.0117

Cit 0.5 mg + PQ 2mM

33.33

66.67

<0.0001

Cit 1.0 mg + PQ 2mM

42.22

57.78

<0.0001

Cit 2.0 mg + PQ 2mM

37.78

62.22

<0.0001

72
Cit 0.5 mg + PQ 2mM
Cit 1.0 mg + PQ 2mM
Cit 2.0 mg + PQ 2mM

WT-N2

Cit 0.25 mg + PQ 2mM

72
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Figure 34. Effect of Cit CQDs and Paraquat on Survival Paraquat-Treated Tg C.
elegans. (A) Cumulative plots of BZ555 C.elegans treated with Paraquat at a concentration of 1mM to
4mM.(B) % survival plot of worms treated with Cit CQDs after 72-hour CQDs at concentration of
0.25mg-2mg. (C) Representative survival cumulative plot with worms pretreated with Cit CQDs and
Paraquat. The data represent the survival ratio (approximately 45-50 animals per group). Data is
representative of the average of at three independent trial that were pooled and analyzed using online
application for the survival analysis of lifespan assays (OASIS;
http://sbi.postech.ac.kr/oasis/introduction/).

105

6.2.5

Cit CQDs Protected Dopaminergic Neurons of Tg C. elegans
We assessed the protective effect of Cit CQDs on the Paraquat-induced toxicity and

neurodegeneration of dopaminergic neurons of the transgenic BZ555 (Pdat-1:GFP; GFP expressed
explicitly in dopaminergic neurons). BZ555 worms possess 302 neurons, but only 8 are DA
neurons. The selective neuroprotection of these DA neurons was observed through the treatment
of Cit CQDs. Worms treated with Paraquat exhibited less green intensity and the highest
percentage of neurodegeneration.
We found that ADE neurons showed either a slight reduction or complete loss of GFP
expression intensity, at least in one of the ADE neurons. By contrast, CEP was slightly affected or
remained intact after treatment. We did not observe any differences in the PDE neurons after
Paraquat treatment (Figure 35 A-B). Cit CQDs at a 1.0 and 2.0 mg/ mL concentration exhibited a
significant protective effect against Paraquat-induced loss of GFP signal (p < 0.05). Furthermore,
we evaluated the percentage of neuroprotection of the nematodes after being treated with Cit
CQDs. We considered a worm was neurodegenerated if one of the six head neurons exhibited
degeneration after Paraquat treatment (see details in "Materials and methods" chapter 3) (Figure
35 C-G). Figure 35 C-F demonstrates how the dendrites and the CEP or ADE neurons were
affected or simply completely disappeared as a function of Paraquat treatment. However, the
worms that were pre-treated with the CQDs protect the DA of the toxicant. All concentrations of
CQDs exhibited significant neuroprotection (p < 0.05) (Figure 35 G). Finally, our result suggests
that Cit CQDs could completely protect BZ555 DA neurons of Paraquat-mediated DA neuronal
loss.
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Figure 35. GFP Expression in Dopaminergic Neurons of Tg C. elegans
(BZ555). DA neurons (CEP and ADE) in the head were counted in each survived animal by
evaluating the GFP fluorescence intensity. Representative images of the effects of Cit CQDs on
restoration of Paraquat induced DA neuron-degeneration in C. elegans as indicated by the GFP
expression in DA neurons. (A) Mean intensity of worms treated with Cit CQDs on a range of
0.25mg to 2.0 mg/mL. (B) Represent the mean intensity of C. elegans, pretreated with Cit
CQDs for 24 hours and then exposed to Paraquat (2mM) for 72 hours. (C-F) Representative
images of the six fluorescence signals of DA neurons. (G) Represent the percentage of worms
that presented neurodegeneration. All worms were analyzed at 20X magnification using Zeiss
confocal microscope. Bar scale represent 50µm. Data are expressed as the mean ± S.D. and
results are obtained from three in- dependent assays. *p < 0.05 compared with control-treated
worms.
6.3

DISCUSSION
PD is characterized by excessive oxidative stress, mitochondria damage, synaptic loss,

abnormal dopamine metabolism, aggregation of amyloidogenic proteins, degeneration of DA, and
the dysfunction of different pathways essential for brain functioning. Several studies have
demonstrated that Paraquat is an environmental chemical neurotoxin that has been linked to PD.
It undergoes a one-electron reduction in cells that can uptake and provoke nitrosative /oxidative
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stress.228 Multiple studies have demonstrated that when animals have been exposed to Paraquat,
they develop behavioral and biochemical changes that resemble PD symptoms, such as rigidity,
slow movement, akinesia, tremor, and decreased DA concentration. Previous work has used the
SH-SY5Y neuroblastoma cell line as an in vitro model to study the effect of Paraquat on biological
systems. SH-SY5Y presents multiple features of nervous system (NS) neurons, and it is used to
target neuronal cells. Consistent with previous results, Paraquat induced neurotoxicity, cell death,
apoptosis, and ROS production to the SH-SY5Y in a dose-dependent manner.228,231
In this study, we designed a mechanism for assessing the prophylactic effect of Cit CQDs
in a cell line (SH-SY5Y) and the Tg C. elegans. We availed of the biocompatibility, low toxicity,
and tunable optical behaviors of the as-synthesized carbon-based nanomaterials to examine their
neuroprotective effects on xenobiotics-induced neurotoxicity. We use the BZ555 C. elegans
strains, which expressed GFP in their eight dopaminergic neurons, including six in the head (two
pairs-CEP) and (one pair-ADE), and also possess (one pair-PDE) in the posterior lateral region. C.
elegans has gained more popularity because its genome has already been fully sequenced.
Additionally, its short life cycle, the transparent body is suitable for imaging, and the cost-effective
conditions made this model ideal for studying human diseases. We used this in vivo model for
CQDs testing because it is a well-established model since the nervous system of C. elegans has
already been studied, and it is easy to visualize the DA neurons in these live animals. The
neuroprotection effect of Cit CQDs was used for inhibiting the toxicity effect of Paraquat-induced
neuronal death and neurodegeneration. We demonstrated that cells pretreated with Cit CQDs could
protect the cell against neurotoxicants and alleviate oxidative stress toxicity. In Figure 32 C, it
was noted that the exposure of Paraquat alone caused a significant increase in SH-SY5Y cell death,
whereas the pretreatment of Cit CQDs could decrease cell death. This study reported that the
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neuroprotective function of Cit CQDs was also able to reduce the ROS induced by Paraquat.
Previous studies have demonstrated that Paraquat affects the lifespan of C. elegans. In this study,
we assessed the viability of the nematodes using different concentrations of Paraquat, Cit CQDs,
and pretreatment of the CQDs before the Paraquat insult. The survival rate in C. elegans treated
with Cit CQDs was reported with significant outcomes. The result reported that Cit CQDs
protected the worms from Paraquat-induced oxidative stress. The mechanism behind the benefits
of CQDs at different concentrations is their antioxidant capability.
Finally, pretreatment of Cit CQDs improves the lifespans and reduces the mortality of
worms after Paraquat. It is known that the exposure of neurotoxins such as MPTP, 6-OHDA,
Rotenone, and Paraquat drive the activation of microglia signaling pathways, oxidative stress, and
damage to neurons of PD patients and animals’ models. This study showed that Paraquat-mediated
oxidative stress and induced the disruption of dopaminergic neurons of the nematodes BZ555. We
found that Cit CQDs attenuated the expression of DA neurons and demonstrated that the
antioxidant effects of these carbon nanomaterials diminished the level of these neurons. However,
the mechanism by which CQDs work in the nematodes needs further clarification.
6.4

CONCLUSION
Some neurodegenerative diseases are multifactorial and are influenced by age, genetics

and, environmental chemical factors such as insecticides, pesticides, and herbicides. These
environmental toxicants contribute to the neurotoxicity related to many neurodegenerative
disorders, like PD—the mechanism by which some of these compounds work is causing oxidative
stress and nigrostriatal damage. Our research suggests that a carbon nanomaterial synthesized by
easy methods, such as the hydrothermal with biocompatible and antioxidant characteristics, can
be protective in vitro and in vivo models against the oxidative stress induced by environmental
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toxicants. Cit CQDs can protect the human neuroblastoma SH-SY5Y cell line and the
dopaminergic neurons in C. elegans nematodes from the Paraquat-induced neuronal cell death
through suppressing ROS level, which would lead to neurotoxicity. Conclusively, Cit CQDs might
serve as a valuable candidate for the development of neurodegenerative diseases therapy.
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Chapter 7
Conclusion
Many neurodegenerative diseases (NDs), specifically Alzheimer’s disease (AD) and
Parkinson’s disease (PD), have gained much more attention in the last decades due to their high
incidence worldwide as the population ages. It is alarming to know that no cure for these diseases
exists. Only medications and management strategies help treat the symptoms. Even though the
etiology of NDs is still unclear, we know more now than a few decades ago. We know that
endogenous genetic factors contribute to the etiology of the disease, but exogenous factors such as
environmental exposure (pesticides, metals) also predispose to the development of these disorders.
How about designing a therapy that prevents us from developing the disease or cures
people when the disease is already there? In some cases, even both can coexist. This dissertation
aims to create disease models that help us better understand the etiology of AD and PD and their
outcomes, and at the same time, evaluate the effectiveness of models to design innovative
therapies.
Mounting evidence from many previous works has shown that AD and PD patients at the
preclinical stage of the disease present a significant level of oxidative stress and aggregation of
disease pathological proteins. We have used the dopaminergic neuroblastoma cell line SH-SY5Y
and the peptide Aβ (25−35) to address these issues, which reproduces the cardinal phenotypes
associated with AD. When the cells were insulted with Aβ peptide. As a result, we observed an
elevated level of reactive oxygen species (ROS), cellular dysfunctions, apoptotic cell death, and
protein aggregation, which influence cellular homeostasis. Looking for the ideal compound against
the neurotoxicity exerted by Aβ (25−35), we tested the neuroprotective effect of Brazilin. The
pretreatment with Brazilin protected the cells from oxidative damage and apoptotic cells death.
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This plant natural antioxidant compound was also found to mitigate Aβ (25−35)-induced
alterations of necessary housekeeping machinery and protein disulfide isomerase (PDI), and αSynuclein (α-Syn), which are essential biomarkers associated with PD pathogenesis.
Moreover, our data suggest that Brazilin acts as an anti-fibrillary agent in the lysozyme
protein aggregation, which simulated the aggregated mechanism found in many NDs. Thus, via
this result, we concluded that Brazilin appears to inhibit Aβ fibrillization. Our findings indicate
that Brazilin is an excellent neuroprotective and anti-fibrillary agent that helps resist Aβ (25−35)induced cross-toxicity and amyloidogenic onset found in AD and PD. We also tested the toxicity
of different variants of oligomeric Aβs (WT, Aβ (25-35), Reversed (35-25), and Scrambled). Our
findings demonstrate that reversed and scrambled Aβ do not show any propensity of self-seeding
nor any sign of aggregation. Thus, no toxicity behavior in cells was observed. However, the WT
form of Aβ (25-35) leads to cytotoxicity and exerts higher apoptotic cell death. Because of the
result obtained, we used this variant for all downstream experiments.
Over the past few years, convincing evidence has demonstrated the cross-protein pathology
feature and the overlapping clinical symptoms in many NDs. This explains why aggregated Aβ
has been found to overlap with α-Syn in Lewy bodies and Lewy neurites in AD, accounting for
40% of the cases. Conversely, α-Syn pathology has co-occurred with Aβ in about >80% of the
cases. Previous studies found that α-Syn pathology interacts with Tau proteins in about 50% of
the cases. Therefore, it is believed that there is a common mechanism that lies behind the
convergence to co-morbidity seen in the majority of NDs. Taken together, we can conclude that
the mechanism responsible for these pathological proteins and interacting symptoms is due to a
self-seeding mechanism that acts as prion-like protein and create a gradual, systematic spread. This
mechanism is an important factor in the NDs process because it can recruit similar soluble proteins
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and spread throughout the brain, which tends to drive cross-toxic outcomes. Therefore, to
understand the amyloid self-seeding and the spreading mechanism, we designed a hybrid rodent
model to study amyloid cross-toxicity by infiltrating an amyloid protein into a heterotypic neuron
that is not endogenously expressed. We were interested in knowing what the behavioral and
molecular outcomes might be after this infiltration.
We decided to address this question using WT- rats, in which we stereotaxically infuse the
oligomeric form of Aβ in two different forms, viz the full length (1-42) and a short length (25-35),
into the midbrain (Tegmentum) locus. Our study suggests that Aβ might behave as a prion-like
protein and influence the aggregation of itself and interact with other unrelated prion-like proteins.
This interaction might drive their accumulation and corrupt important protein status or simply act
synergistically to influence to form cross-toxic outcomes. When designing this model, we
hypothesized that the Aβ infiltration into the midbrain proximate to the SN would result in the
dopaminergic neuron (DA) depletion in the ipsilateral side. As a result, this would lead to
degeneration in the contralateral side by eliciting motor impairments. However, we did not observe
significant motor impairment in the four different behavioral studies following Aβ infusion.
Conversely, we found significant molecular outcomes resulting from the Aβ infiltration,
such as the accumulation of PD pathological protein (Phosphorylated α-Synuclein (Pα-Syn), the
interaction between Pα-Syn and Thioflavin S dye, which stains amyloid proteins, and the
colocalization of Pα-Syn and Ubiquitin. Together, our finding was sufficient to create a prion-like
mechanism and aggregate pathological disease proteins, and established a progressive
neurodegenerative model exhibiting significant molecular outcomes. However, we propose some
modifications for future studies, which have to determine whether increasing the concentration by
first doing a dose-response curve, injecting within the SNpc, or creating a chronic infusion via an
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osmotic pump can increase the magnitudes of the degeneration to observe functional deficits to
emerge.
Many environmental toxicants are known to increase the production of free radicals. This
dissertation aimed to understand the association between the neurotoxins found in the environment
(pesticides, herbicides, metal exposure, etc., the oxidative stress involved in NDs, and the ability
of Carbon Quantum dots (CQDs) to prevent it. To answer this question, we evaluate Citric Acid
CQDs (Cit CQDs) on DA neurodegeneration in the nematodes C. elegans. The result obtained
show that Cit CQDs pretreatment could successfully increase the survival rate of the worms under
Paraquat exposure. Additionally, Cit CQDs also protected against the Paraquat-induced
neurodegeneration in some of the eight DA neurons of the worms possible by the modulation of
oxidative stress. Based on these findings presented in this dissertation, we suggest that the models
presented here have a potential role in understanding, designing, and targeting the etiology of many
NDs and thus creating potential therapeutic drugs.
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Glossary
6-OHDA

6-Hydroxydopamine

α-Syn

Alpha-Synuclein

Aβ

Amyloid-Beta

AA

Ascorbic Acid

AD

Alzheimer’s Disease

ALS

Amyotrophic Lateral Sclerosis

ADE

Anterior Deirid

APP

Amyloid Precursor Protein

ANOVA

Analysis of Variance

Braz

Brazilin

BSA

Bovine Serum Albumin

CEP

Cephalic sensilla

Cit

Citric Acid

CNS

Central Nervous System

CGC

Caenorhabditis Genetics Center

CNMs

Carbon Nanomaterials

CNTs

Carbon Nanotubes

CQDs

Carbon Quantum Dots

DA

Dopamine

DAPI

4′,6-diamidino-2-phenylindole

DLB

Dementia with Lewy Body

DLS

Dynamic Light Scattering

DPPH

1,1- diphenyl-2-picryl-hydrazyl

DMSO

Dimethyl Sulfoxide
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ER

Endoplasmic Reticulum

EGCG

Epigallocatechin Gallate

EODA

Early-Onset Alzheimer’s Disease

FAD

Familial Alzheimer’s Disease

FBS

Fetal Bovine Serum

FTD

Frontotemporal Dementia

FT-IR

Fourier-transform infrared spectroscopy

GI

Gastrointestinal

GFP

Green Fluorescent Protein

GPx

Glutathione peroxidase

HEWL

Hen Egg-White Lysozyme

HFIP

Hexafluoro isopropanol

HD

Huntington’s Disease

H2DCFDA

2',7'-dichlorodihydrofluorescein diacetate

IF

Immunofluorescence

IACUC

Institutional Animal Care and Use Committee

LB

Lewy Body

LN

Lewy Neurite

LBD

Lewy Body with Dementia

LOAD

Late-Onset Alzheimer’s Disease

MAPT

Microtubule Association Protein Tau

MOC

Mander's overlap coefficient

M1,2

Mander’s 1& 2

m.p.i

Months Post-infusion

mHtt

Mutant Huntingtin Protein

MPTP

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

NADPH

Nicotinamide adenine dinucleotide phosphate
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NGM

Nematodes Growth Media

NDs

Neurodegenerative Diseases

NNDs

Non-neurodegenerative disorders

NFTs

Neurofibrillary tangles

NTG

Non-Transgenic

NGS

Normal Goat Serum

Pα-Syn

Phosphorylated α-Synuclein

PD

Parkinson’s Disease

PDD

Parkinson’s Disease with Dementia

PFA

Paraformaldehyde

PCC

Pearson correlation coefficient

Prx

Peroxiredoxin

PAGE

Polyacrylamide gel electrophoresis

PVDF

Polyvinylidene Difluoride Filter

PDE

Posterior Deirid

PTMS

Post-translational modifications

PLQY

Photoluminescence quantum yield

PBS

Phosphate Buffered Saline

PBST

Phosphate Buffered Saline TWEEN TM 20

PSEN1

Presenilin 1

PSEN2

Presenilin 2

PDI

Protein Disulphide Isomerase

PI

Propidium iodide

Pdat-1

Dopamine transporter

ROS

Reactive Oxygen Species

RNS

Reactive Nitrogen Species

SD

Standard Deviation
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SEM

Standard Error of the Mean

SOD

Superoxide Dismutase

SN

Substantia Nigra

SNpc

Substantia Nigra pars compacta

SNCA

Synuclein Alpha

TDP-43

TAR DNA-binding protein 43

TEM

Transmission electron microscopy

Tg

Transgenic

THT

Thioflavin T

ThS

Thioflavin S

TH

Tyrosine hydroxylase

UPS

Ubiquitin-Proteasome System

WT

Wild-Type
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Appendix
Summary of behavioral data corresponding to chapter 5.

Appendix 1. Time to contact after Aβ infusion

Appendix 2. Time to removal after Aβ infusion
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Appendix 3. Total time of sticky dot test
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Appendix 4. Cylinder test after Aβ infusion

Appendix 5. Ladder test after Aβ infusion
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Appendix 6. Wire hang test after Aβ infusion

Appendix
The purpose of this pilot study was first to find out the mechanism by which these two
diseases overlap and conduct an in vitro and in vivo studies with the purpose to study find
molecular mechanism similitudes and then target with plant-based compounds. We hypothesized
that one pathology may appear as a toxicant that is acting as a factor to provoke the other disease
to occur. At the molecular level, it has demonstrated by a previous student in the laboratory, how
the peptide (AD biomarker) can initiate a cascade of event that signals the onset of PD. Alongside
with this project we examined whether the behavioral and cellular results can be translated to the
animal model.
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At this level, the focus of the pilot study was to evaluate any pathobiobehavioral deficit
associated whit the introduction of an Alzheimer's (AD) associated protein into the substantia nigra
pars compacta (the place where PD start) of the rodent brain. The development of a rodent model
for this pilot study informed us of the translational relevance of these intracellular findings to do
it in larger scale and longer time point. The results of the full study are found in chapter 5.

Appendix 7. Behavioral assessment of Lewis rats at 90 days after a single
unilateral infusion of vehicle, oligomeric Aβ25-35, and oligomeric Aβ1-42 (n= 5, 7, and 7,
respectively). (A and B) Here, performance on the cylinder test and the wire hang test are
shown. For the cylinder test, total number of paw touches were counted for a 120 s period;
for the wire hang test, latency to fall was measured for 3 trials and averages are shown here.
In both tests, rats treated with oligomeric AB25-35 showed deficits as compared to the vehicle.
(C and D) The ladder test involved quantifying the number of foot slips over a 60 cm
trajectory, totals for one trial are shown here. For the adhesive removal test, three trials were
performed to measure the amount of time it took the rat to remove the stimuli from the
moment it came to contact with it, averages of three trial are shown here. Data are mean
values +/- SE; differences were established with a student’s T-test, *p <0.05, **p <0.01.
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Appendix 8. Examination of tyrosine hydroxylase (TH+) post aβ infusion. (A)
western blot analysis of striatal th+ from rat 3 m.p.i (n=3 rat per group) using anti-TH antibodies
and anti-actin as loading controls protein . (B) quantification of band density, protein level
detected among control were normalized to the levels of actin. (C) Representative image of
immunofluorescence of TH+ neuron in the SNpc) using anti-TH antibodies. Quantitative data are
expressed as mean ± SD.
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